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ABSTRACT 
 
Though most types of thyroid cancer are cured by surgery and adjuvant radio-
iodine therapy and TSH suppression, patients with radio-iodine refractory 
thyroid carcinoma as well as with medullary thyroid carcinoma, a 
neuroendocrine malignancy that does not express iodine transporter, are 
difficult to treat because of the lack of effective systemic treatment. Therefore, 
there is an urgent need of novel therapeutic measures for these patients. 
Thyroid cancer is frequently associated to the oncogenic conversion of protein 
kinases such as RET (medullary thyroid cancer) and BRAF (papillary and 
undifferentiated thyroid cancer). Therefore, protein kinase small molecule 
inhibitors (PKI) have been considered as promising novel agents for the 
treatment of thyroid carcinoma. Compounds that revealed good RET and 
BRAF activity both in clinical (vandetanib for RET) and in pre-clinical 
(vemurafenib for BRAF) settings have been identified. Recently, vandetanib 
was approved for patients with medullary thyroid carcinoma and vemurafenib 
was approved for patients affected by melanoma. Cancer patients may be 
refractory to PKI or develop secondary resistance after an initial response. 
Two general mechanisms can explain resistance: i) the presence of mutations 
in the kinase that blocks binding to the PKI; ii) the oncogenic switch to 
another pathway that rescues cancer cells from kinase blockade. In this 
dissertation, we have addressed mechanisms of resistance in the case of RET 
PKI (for the treatment of medullary thyroid carcinoma) and BRAF PKI (for 
the treatment of radio-iodine refractory thyroid carcinoma). Here we show 
that: i) ponatinib is a novel RET PKI and is able to overcome RET resistance 
mediated by mutations in RET V804 and Y806; ii) thyroid cancer cells escape 
treatment with vemurafenib by switching to another signaling pathway and 
that inhibitors of the IGF1R/PI3K/AKT signaling cascade may be exploited to 
overcome resistance of thyroid cancer cells lines to BRAF PKI. 
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1. INTRODUCTION 
 
 
1.1 Thyroid gland 
 
The thyroid gland is composed of two distinct hormone-producing 
cells: follicular cells (producing thyroid hormones) and parafollicular C cells 
(producing calcitonin). Most of the thyroid follicular cells are derived from the 
endodermal diverticulum, whereas a few of them derive from the 
ultimobranchial body. The parafollicular cells are neural crest derived; they 
originate from the ultimobranchial body and are interspersed in small groups 
among the follicles in the intermediate part of the thyroid lobes (DeLellis et al. 
2004; Kondo et al. 2006). Follicular cells concentrate inorganic iodide from 
the bloodstream to produce the hormones thyroxine (T4) and its bioactive 
derivative triiodothyronine (T3) from thyroglobulin. The parafollicular C-cells 
secrete calcitonin, which is involved in bone metabolism. Calcitonin secretion 
is stimulated by elevated calcium concentration in the serum. 
 
 
1.2 Thyroid Carcinoma 
 
 Benign thyroid lesions are typically solitary adenomas. They can be 
clinically silent or hyper-functioning (referred to as a toxic thyroid adenoma), 
thereby causing hyperthyroidism. Gain-of-function mutations of TSHR 
(~80%) and GNAS1, encoding GαS, (~25%) are the most common genetic 
lesion in functional thyroid adenomas, whereas these genetic lesions did not 
occur in thyroid malignancies (Kondo et al. 2006).  
Malignant thyroid lesions are the most common cancers of endocrine 
organs and represent approximately 1% of newly diagnosed cancer cases 
(DeLellis et al. 2004), with an incidence rate stably increasing over the past 
few decades (Jemal et al. 2010). Tumors deriving from follicular cells 
represent more than 95% of thyroid cancers, whereas only 3-5% of them arise 
from C-cells. On the basis of histological and clinical parameters, malignant 
follicular-derived lesions are classified into well-differentiated carcinomas 
(WDTC) in turn including papillary (PTC) and follicular (FTC) carcinomas, 
poorly differentiated carcinomas (PDTC), and anaplastic carcinomas (ATC) 
(DeLellis et al. 2004, Kondo et al. 2006).  
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1.2.1 Papillary Thyroid Carcinoma (PTC) 
 
PTC is the most prevalent thyroid cancer subtype (80% of cases) 
(DeLellis et al. 2004). PTC is characterized by typical features of the cell 
nuclei, including enlarged, vesicular and overlapping nuclei with clearing, fine 
dusty chromatin, grooves, inclusions and single or multiple micro- or 
macronucleoli. PTC is closely linked to radiation exposure and its incidence 
sharply increased in children after the Chernobyl accident (Williams 2008). 
Over 70% of PTC feature genetic alterations causing activation of the 
MAPK pathway (Kondo et al. 2006; Nikiforov et al. 2011) (Table 1). PTC is 
characterized by mutations of various MAPK components, including 
rearrangements of the RET (REarranged during Transfection) tyrosine kinase 
receptor, or more rarely NTRK1, or activation of BRAF (B-type RAF family 
kinase). RET/PTC and BRAF alterations are mutually exclusive in PTC, 
suggesting that mutations at more than one of these sites are unlikely to confer 
additional biological advantage, a fact that is consistent with the overlap of the 
signaling pathways of these oncoproteins. Specific PTC subtypes have 
different mutation patterns. For example, FV-PTC (follicular-variant PTC), 
when encapsulated, frequently (up to 40%) harbors mutations in RAS (Rivera 
et al. 2010), In contrast, infiltrative FV-PTC often (25%) harbors BRAF 
mutations. BRAF mutant FV-PTC may harbor the K601E or other alternative 
mutations rather than the classical BRAF V600E (Xing 2007). Compared to 
FV-PTC and classical PTC, TCV-PTC (tall-cell variant PTC) shows a high 
(up to 80%) proportion of BRAF V600E positive cases (Nikiforova et al.  
2003). 
 
 
1.2.2 Follicular Thyroid Carcinoma (FTC) 
 
FTC accounts for about 10% of all thyroid malignancies, though the 
incidence may be declining relative to PTC (DeLellis et al. 2004). FTC can be 
hardly differentiated from FTA (Follicular Thyroid Adenoma) and possibly 
some FTC may have evolved from pre-existing FTA. FTC shares some 
genetic alterations with FTA (Kondo et al. 2006). One group of FTC is 
associated with RAS gene mutations while the RAS mutation-negative FTC 
subgroup often features gene rearrangements of PPARG, most commonly the 
PAX8-PPARG fusion (Table 1). RAS and PAX-PPARG do not overlap and 
together they explain up to 80% FTC cases (Nikiforov et al. 2011).  
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1.2.3 Poorly-Differentiated Thyroid Carcinoma (PDTC) 
 
PDTC are rare neoplasms characterized by a partial loss of 
differentiation and less favorable prognosis in comparison with WDTC 
(Volante et al. 2010). Diagnostic criteria for PDTC include the presence of a 
solid-trabecular-insular pattern of growth, absence of the nuclear features 
typical of PTC and the presence of at least one of these features: convoluted 
nuclei (small hyperchromatic nuclei with convolutions of the nuclear 
membrane); high mitotic; and tumor necrosis (Volante et al. 2010). PDTC 
have genetic features intermediate between WDTC and ATC. Similar to 
WDTC, PDTC harbours mutations in RAS or, less frequently (15%) in BRAF 
(Table 1). 
 
 
Table 1: Genetic lesions associated to thyroid carcinoma 
Genetic 
alteration 
Function PTC FTC PDTC ATC MTC 
RET/PTC 
rearrangement 
Receptor 
tyrosine kinase 
20%  rare   
TRK-T 
rearrangement 
Receptor 
tyrosine kinase 
5-13%     
RET mutation Receptor 
tyrosine kinase 
    50% 
MEN2: 
95% 
BRAF mutation Serine threonine 
kinase 
45%  15% 44%  
RAS mutation Small GTPase 10% 50% 44% 20-60%  
PIK3CA 
mutation 
Lipid kinase rare rare rare 20%  
PPARG 
rearrangement 
Nuclear receptor  35% rare   
TP53 Transcription 
factor 
rare rare 15-30% 60-80% rare 
 
 
Similar to ATC, PDTC features in some cases mutations in TP53 (15-
30%) or in PIK3CA (phosphoinositide-3 kinase) and its downstream effector 
AKT (Ricarte-Filho et al. 2009). RAS (predominantly NRAS codon 61) 
mutations are the most prevalent genetic lesions found in PDTC and are being 
identified in up to 44% of cases (Ricarte-Filho et al. 2009; Volante et al. 
2010).  
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1.2.4 Anaplastic Thyroid Carcinoma (ATC) 
 
ATC accounts for 2–5% of all thyroid cancers. More than 25% of ATC 
patients have coincidentally detected well-differentiated (PTC or FTC) 
carcinoma, suggesting their tumors derive from pre-existing PTC or FTC 
(DeLellis et al. 2004; Kondo et al. 2006). In up to 75% of ATC cases, there is 
an evidence of distant metastases at diagnosis and the median survival of ATC 
patients is 5 months (Smallridge and Copland 2010). Chemotherapy is 
ineffective in ATC and only partial responses are obtained in less than 25% of 
cases (Smallridge and Copland 2010).  
Genetically ATC is associated with BRAF and RAS mutations whereas 
RET/PTC and TRK-T mutations are not found (Table 1). BRAF mutations are 
mainly found in samples containing a PTC component, thus supporting the 
notion that these ATC may derive from a pre-existing PTC (Nikiforova et al. 
2003).  Additional mutations identified in ATC include mutations in beta-
catenin and in TP53 tumor suppressor, lesions that are rarely found in WDTC 
(Table 1). TP53 loss-of-function is likely critical for the establishment of the 
ATC phenotype. In a recent gene expression profiling paper, a set of 
chromosomal instability and cell proliferation genes were found up-regulated 
in ATC and such upregulation was mechanistically linked to TP53 mutation 
(Salvatore et al. 2007). Finally, mutations targeting components of the 
phosphoinositide-3 (OH) kinase (PI3K) signaling cascade were found in ATC 
and less frequently in WDTC (Saji and Ringel 2010).  
 
1.2.5 Medullary Thyroid Carcinoma (MTC) 
 
 MTC accounts for about 5% of all thyroid cancers (Schlumberger et al. 
2008). MTC is sporadic in about 75% of cases, and in the others it is a 
component of the autosomal dominant cancer syndrome known as “multiple 
endocrine neoplasia type 2” (MEN2). MEN2 includes three subtypes: MEN2A 
(about 80% of cases), MEN2B and familial MTC (FMTC) (Waguespack et al. 
2011). MEN2-associated hereditary MTC is typically bilateral and 
multicentric and it is usually preceded by multifocal C-cell hyperplasia 
(CCH). In MEN2A, MTC is associated with pheochromocytoma, parathyroid 
hyperplasia and, rarely, cutaneous lichen amyloidosis (CLA) and 
Hirschsprung’s disease. In MEN2B, MTC is associated with 
pheochromocytoma, multiple ganglioneuromas of the lips and gastrointestinal 
tract and marfanoid body habitus. Our knowledge of the genetic lesions 
associated with MTC is still very limited. Genes commonly mutated in other 
types of cancer - as well as other thyroid cancers - like BRAF, PIK3CA and 
TP53 - are not commonly mutated in MTC. Mutations in the RET proto-
oncogene is present in about half of sporadic cases and virtually all familial 
cases (Table 1). Importantly, RET mutations correlate with a more aggressive 
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MTC phenotype and blood screening for RET mutations can be used to 
identify patients with familial form of MTC (Elisei et al. 2008; Romei et al. 
2011). In some cases, RET gene amplification has been reported (Ciampi et al. 
2012). Recently, RAS mutations have been found in RET-negative MTC cases 
(Moura et al. 2011) 
 
 
1.3 RET 
 
 The RET proto-oncogene is located on chromosome 10q11.2 and 
encodes a transmembrane receptor tyrosine kinase (RTK) with four cadherin-
related motifs in the extracellular domain (Santoro et al. 2006). RET is 
normally expressed in the developing central and peripheral nervous system 
and is an essential component of a signaling pathway required for renal 
organogenesis and enteric neurogenesis. RET is normally expressed at high 
levels in C-cells, but not in follicular cells (Santoro et al. 2006). Glial cell line-
derived neurotrophic factor (GDNF)-family ligands and GDNF-family 
receptor α (GFRα) bind the extracellular domain of RET inducing its 
dimerization. This active form of RET autophosphorylates specific tyrosine 
residues within its intracellular domain, that function as binding sites for 
signaling molecules containing phosphotyrosine-binding motifs (SH2 or PTB), 
thereby activating several signaling pathways (Santoro et al. 2006). Through 
phosphorylated Y1062, RET binds SHC and FRS2, that recruit Grb2-SOS 
complexes leading to the activation of the RAS-RAF-ERK cascade (Borrello 
et al. 1994). Through pY1062, RET is also able to activate the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway (Santoro et al. 2006) 
(Figure 1). 
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Fig. 1: The RET structure and signaling network. The structure of the RET 
protein and its signaling network with the docking sites and targets. 
  
 
As mentioned above, gain-of-function mutations of RET are involved 
in sporadic MTC and FMTC, including MEN2A and MEN2B (Figure 2). In 
95% of cases, MEN2B patients carry the M918T mutation in the RET kinase 
domain; the remaining fraction harbors the A883F substitution or other rare 
mutations. In 98% of MEN2A and 90% of FMTC cases, mutations affect one 
of the five cysteines in the extracellular cysteine-rich domain of RET. The 
remaining cases have mutations in few other codons mainly located in RET 
exons 13, 14, or 15 (Figure 2). Somatic mutations of RET, which mainly 
target V804, M918 and E768, are found in about half of sporadic MTC. All 
these mutations activate RET converting it into a dominantly transforming 
oncogene (Santoro et al. 2006; Wells et al. 2009). However, the various 
mutations have different oncogenic potential and this represents the basis for 
the different timing of prophylactic thyroidectomy according to the MTC 
guidelines (Pacini et al. 2010; Kloos et al. 2009; Waguespack et al. 2011). 
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Fig. 2: Schematic representations of most common RET mutations 
associated to MTC.  
 
 
 Conversely, PTCs are characterized by chimeric oncoproteins named 
RET/PTC, originating from the in-frame fusion of the RET tyrosine kinase 
encoding domain and 5’-ter of different partner genes (Kondo et al. 2006) 
(Figure 3). RET/PTC lacks RET signal peptide and transmembrane domains 
but retains the kinase domain and most of the autophosphorylation sites, 
thereby allowing downstream signaling. By providing an active transcriptional 
promoter, RET/PTC rearrangements enable thyroid expression of the chimeric 
RET/PTC oncoproteins. To date, more than 10 RET/PTC rearrangements have 
been described; the most frequent are RET/PTC1, which involves RET and H4 
(CCDC6) genes and RET/PTC3, between RET and RFG (RET-Fused Gene) 
(also named NCOA4, ELE1 or ARA70) (Kondo et al. 2006). RET/PTC 
rearrangements are found in about 20% of PTC, with higher prevalence in 
classic form than in follicular variant (Kondo et al. 2006; Nikiforov et al. 
2011). Their prevalence is significantly higher in young age patients and in 
patients with a history of accidental or therapeutic radiation exposure.  
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Fig. 3: Schematic representation of RET/PTC rearrangements in PTC 
 
 
Moreover, at a variance from BRAF (see below), RET/PTC doesn’t 
seem to be a negative prognostic factor for PTC (Xing 2007). The low 
prevalence of expression of RET/PTC oncoproteins in PDC and ATC suggests 
that they do not play a prominent role in thyroid tumor progression (Nikiforov 
et al. 2011).  
  
1.4 BRAF 
 
 BRAF (7q24) is a member of the RAF kinase family of serine/threonine-
specific protein kinases, comprising three members: ARAF, BRAF and CRAF 
(or RAF-1) (Chong et al. 2003). Homologues of the three corresponding genes 
are found in all vertebrates, while a single RAF gene exists in invertebrates 
(for example, DRAF in Drosophila melanogaster and lin-45 in Caenorhabditis 
elegans), whose sequence is most closely related to BRAF. The RAF gene 
products are RAS effectors participating to the ERK (MAPK) signaling 
pathway. ERK/MAPK pathway, in turn, connects extracellular signals to 
transcriptional regulation (Schubbert et al. 2007). RAS is activated by growth 
factors and hormones and in turn activates multiple downstream pathways 
controlling cellular survival, proliferation and differentiation. In its active 
GTP-bound state it binds to RAF proteins (also named MAPKKK), thereby 
recruiting them to the plasma membrane. Once localized at the membrane, 
RAF kinases are activated by a series of phosphorylation and 
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dephosphorylation events. BRAF and CRAF can also heterodimerize in 
response to mitogenic signals and the activity of the complex requires at least 
one of the two monomers to be active. Activated RAF proteins phosphorylate 
and activate MEK1 and MEK 2 (MAPKK), which in turn phosphorylate and 
activate ERK1 and ERK2 (MAPK). ERKs phosphorylate several cytoplasmic 
and nuclear targets, including transcription factors such as Ets-1, c-Jun and c-
Myc. The multiple steps in the RAS/RAF/MEK/ERK pathway provide a 
mechanism of signal amplification as well as a platform for signal modulation 
by other factors (Figure 4). 
 
 
 
Fig. 4: Schematic representation of MAPK pathway. 
 
 The RAF proteins display a common architecture with two N-terminal 
regulatory domains (CR1 and CR2) and one kinase C-terminal domain (CR3). 
The three RAF members show differences in tissue distribution and activation 
modalities. Importantly, several residues must be phosphorylated in ARAF 
and CRAF for full activation, while some of them are constitutively 
phosphorylated or replaced with phosphomimetic residues in BRAF. This 
makes BRAF activation more rapid and efficient than that of CRAF or ARAF 
(Figure 5). Accordingly, BRAF has a strong basal kinase activity and is the 
most potent activator of MEK in many cell types; this may account for the 
high prevalence of mutations in BRAF rather than other RAF family members, 
in human tumors (Dhomen and Marais 2007). In fact, BRAF can be activated 
by single amino acid substitutions, while CRAF and ARAF require at least 
two mutations for oncogenic conversion (Dhomen and Marais 2007). 
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Fig. 5: Schematic representation of the RAF proteins. The three conserved 
regions: CR1 (yellow), CR2 (orange) and CR3 (red) are highlighted. The 
amino acids indicated below the individual isoforms refer to known regulatory 
phosphorylation sites. CR1 contains the RAS-binding domain and CR3 
contains the catalytic domain (the activation segment is highlighted in pink).  
 
 
1.4.1 BRAF V600E mutation 
 
 The most common oncogenic mutation in BRAF is the replacement of 
valine 600 with a glutamic acid (Figure 6). BRAF V600E is an oncogenic 
protein with markedly elevated kinase activity that over-activates the MAP 
kinase pathway (Davies et al. 2002; Wan et al. 2004). The BRAF V600E 
mutation occurs in approximately 8% of human cancers and ranks after RAS 
mutation (15%) as the second most common somatic mutation observed in 
human cancer. In comparison to wild-type BRAF, BRAF V600E transforms 
normal cells and does not require RAS function to induce growth of human 
cancer cells. 
 The aliphatic side chain of Val600 interacts with the phenyl ring of 
Phe466 in the P loop of the BRAF kinase. In the V600 mutants, the medium 
sized hydrophobic Val side chain is replaced with a larger and charged residue 
(most commonly Glu, but some times also Asp, Lys, or Arg); this is expected 
to destabilize the interactions that maintain the DFG motif in an inactive 
conformation, thereby flipping the activation segment into the active position, 
thereby activating the kinase in a RAS-independent manner and conferring 
transforming activity. 
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Fig. 6: BRAF mutations found in cancer. The black arrows indicate the 
mutations. The mutations are boxed when they target the same amino acid. 
The hotspot mutation V600E is in red. BRAF exons are also indicated, as well 
as conserved regions CR1, CR2 and CR3. A conserved glycine motif (G-loop) 
in exon 11 is indicated with a red bar and the activation segment (AS) in exon 
15 with a pink bar: the V600E mutation targets the AS. C: Carboxyl-terminal; 
N: Amino-terminal. 
 
BRAF V600E kinase function is activated by approximately 500-fold 
with respect to the wild type protein. Moreover, it induces constitutive ERK 
signaling through hyperactivation of the MEK–ERK pathway, thereby 
stimulating proliferation, survival and transformation (Davies et al. 2002). 
V600E mutation has been observed in melanoma (80%), papillary thyroid 
cancer (44%) and in other tumors (0-18%), including colorectal (5%) and lung 
cancer (1-3%) (Namba et al. 2003).  
Other BRAF mutations include R461I, I462S, G463E, G463V, 
G465A, G465E, G465V, G468A, G468E, N580S, E585K, D593V, F594L, 
G595R, L596V, T598I, A727V, and a few others. Most of these mutations are 
clustered in two regions, the glycine-rich P-loop of the N-lobe and the 
activation segment and flanking regions (Wan et al. 2004) (Figure 6). 
Surprisingly, the activity of some cancer-associated BRAF mutants is 
impaired rather than potentiated. However, these impaired BRAF mutants can 
still activate MEK through CRAF. This BRAF/CRAF interaction, is followed 
by allosteric activation and transphosphorylation of CRAF, thus resulting in 
increased signaling to MEK and ERK (Dhomen and Marais 2007) (Figure 7). 
This mechanism might have important implications in a therapeutic setting; 
indeed, it may explain why cancers with wt BRAF, particularly if positive for 
RAS mutations, are insensitive to BRAF chemical inhibitors (Flaherty et al. 
2010). It may be expected that through the BRAF-CRAF dimerization, BRAF 
inhibitors may even result in an activation rather than block of the MEK 
pathway. 
 As mentioned above, BRAF V600E mutation is predominantly seen in 
melanoma (Davies et al. 2002) and papillary thyroid carcinoma (Cohen et al. 
2003; Kimura et al. 2003; Namba et al. 2003; Soares et al. 2003; Xing et al. 
2004). However, in June 2011, a team of Italian scientists performed massive 
parallel sequencing to pinpoint V600E mutation in 100% of cases of Hairy cell 
leukaemia (Tiacci et al. 2011). 
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Fig. 7: RAS mediates BRAF-CRAF crosstalk. CRAF activity can be 
stimulated, in the presence of active RAS, through dimerization with BRAF. 
This mechanism functions also when BRAF is targeted by loss-of-function 
mutations. This might explain why in some rare cases BRAF mutations found 
in cancer are inactivating rather than activating mutations.  
 
1.5 BRAF V600E mutation in melanoma 
 
 Melanoma is one of the most highly metastatic cancers. It arises from 
melanocytes, and in most of the cases it affects the basal layer of the 
epidermis. Melanoma represents 2% to 3% of malignant tumors in both United 
States and Northern Europe. The incidence of melanoma has doubled in the 
last 20 years; a 4% increase every year is documented in the United States 
(Jemal et al. 2010). Cutaneous melanoma is the most frequently occurring 
melanoma; however, melanoma can occur in other sites, such as the uvea, the 
most frequent melanoma location after skin (Grin et al. 1998). Melanoma has 
metastatic potential greater than other skin cancers such as basal cell 
carcinoma and squamous cell carcinoma. Approximately, 80% of melanomas 
are detected at an early stage in which the tumor is localized in the primary 
site and can be excised (Russo et al. 2009). Melanomas can be classified into 2 
groups, those in the radial growth phase (RGP) and those in the vertical 
growth phase (VGP). RGP melanomas are early lesions and confined, for the 
most part, to the epidermis with a low probability of dissemination. Once 
progressed to the VGP state, tumor cells are highly tumorigenic, and 
characterized by dermal invasion, and distant metastases (Balch et al. 2001; 
Veronesi and Cascinelli 1991). 
  Metastatic melanoma is refractory to conventional therapies and has a 
very poor prognosis, with a median survival rate of only 6 months (Miller and 
Mihm 2006). Chemotherapy is not very effective for melanoma. In a 
prospective randomized controlled trial, adjuvant high-dose interferon was 
shown to increase progression-free (PFS) and overall (OS) survival (Kirkwood 
et al. 1996). Metastatic melanoma is rarely curable with standard 
chemotherapy, although high-dose interleukin-2 (IL-2) has been reported to 
produce durable responses in a small number of patients (Atkins et al. 2000).  
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 In this framework, the most promising melanoma treatment might be 
that targeted to those mutations in transduction/survival pathways that are 
common in melanomas. These targeted therapies may include selective 
inhibitors of the RAF and MEK kinases and inhibitors of the PI3K pathway 
(Russo et al. 2009). Based on the high prevalence of BRAF mutations in 
melanoma, RAF inhibitors have been considered for targeted therapy for 
melanoma. Consistently, a direct correlation has been found between the 
presence of mutated BRAF and melanoma stage, with a higher incidence of 
BRAF mutations in VGP compared to RGP tumors (Dong et al. 2003).  
 
 
1.6 BRAF V600E mutation in thyroid cancer  
 Papillary thyroid carcinoma (PTC) comprises almost 80% of all thyroid 
cancers. As mentioned above, in PTC, mutations of genes encoding effectors 
of the mitogen-activated protein kinase (MAPK) pathway are present in about 
70% of all cases, and include mutually exclusive mutations in BRAF, RAS, 
and RET/PTC or NTRK (Namba et al. 2003; Xing et al. 2004; Kimura et al. 
2003). As in melanoma, most common BRAF mutation in PTC is V600E. An 
intrachromosomal rearrangement between BRAF and AKAP9, leading to the 
expression of a constitutively active form of BRAF has been described, though 
very rarely, in radiation-induced PTC (Ciampi et al. 2005). Prior exposure to 
ionizing radiation during childhood predisposes to development of PTC and to 
RET rearrangements and, to a lesser extent, NTRK or BRAF 
intrachromosomal inversions. These rearrangements are also found in 
pediatric PTC without a history of radiation exposure. In contrast, point 
mutations in BRAF are rare in this population (4–6%) (Xing 2005). Thus, 
somatic mutation of BRAF is the most common early genetic event causally 
associated with the development of PTC in adult patients without a history of 
radiation exposure. 
 BRAF mutation (in most of the cases: V600E) occurs in PTC and PTC-
derived ATC, with a prevalence of 44% in the former and 24% in the latter 
(Xing 2005). In contrast, BRAF mutation does not occur in FTC or other types 
of thyroid tumors. PTCs with BRAF mutation have distinct phenotypic and 
biologic properties. The tall-cell variant (TCV-PTC), an aggressive variant of 
PTC, usually harbors BRAF mutation (Adeniran et al. 2006). PTCs with 
BRAF mutation commonly present at an advanced stage, usually with 
extrathyroidal extension. Some studies suggest that this may reflect the age of 
the patient and not the presence of a BRAF mutation (Trovisco et al. 2005). 
However, others have shown that PTC with BRAF mutation displays an 
increased incidence of locoregional recurrence and a decreased response to 
radioactive iodine. (Nikiforova et al. 2003; Namba et al. 2003; Xing et al. 
2005; Vasko et al. 2005). 
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 BRAF mutations in PTC are probably involved in tumor initiation, as 
they are found in microscopic PTC (microcarcinomas: e.g. PTC smaller than 
10 mm diameter) (Xing et al. 2005). Notably, BRAFV600E is required to 
maintain and promote thyroid cancer progression (Nucera et al. 2010). 
Mechanistically, how BRAFV600E mutation leads to an aggressive PTC 
phenotype is still poorly understood; these mechanisms may include aberrant 
methylation of important tumor suppressor genes (i.e. TIMP-3), up-regulation 
of metallo-proteases-2, -3, -9 and -13 (MMP-2, -3, -9 and -13) (Mesa et al. 
2006; Frasca et al. 2008), reduced expression of thyroperoxidase (TPO) and 
sodium iodide symporter (NIS) (important for iodine metabolism and iodine 
cell uptake) (Romei et al. 2008), and increased chromosomal instability 
(Mitsutake et al. 2005). 
 Thus, the high prevalence and specificity of BRAFV600E for PTC and 
ATC has led to great enthusiasm about the potential clinical utility of this 
mutation as a novel prognostic molecular marker and as an effective target for 
the treatment of PTC (Chiloeches et al. 2006; Espinosa et al. 2007; Groussin 
and Fagin 2007; Lee et al. 2007; Trovisco et al. 2006; Wojciechowska and 
Lewinski 2006; Xing 2006). 
 
 
1.7 Kinases in Cancer  
 
 Kinases and cancer have been intimately linked for 30 years, since the 
first cellular oncogene, SRC, was discovered by Harold Varmus and Michael 
Bishop in 1975, and later found to encode a tyrosine kinase. Over 500 protein 
kinases have been identified to date, including many involved in cellular 
signaling pathways whose dysregulation has been implicated in cancer 
(Manning et al. 2002; Krause and Van Etten 2005). Indeed, many kinases have 
been found to be intimately involved in the processes leading to tumour cell 
proliferation and survival (Table 2). Point mutation, gene amplification or 
translocation, these oncogenic kinases have become impervious to normal 
regulatory mechanisms. Mutated kinases have transforming capacity and are 
therefore considered to be oncogenic.  
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Table 2: Kinases implicated in human cancer 
 
 Kinase Tumor Type  
 
Oncogenic Alteration  
RTK EGFR Breast, lung, glioma Extracellular domain 
deletions & point 
mutations (L858R, G719S, 
& deletions) 
 HER2/ErbB2 Breast, ovarian, colon, lung, gastric Overexpression 
 IGF-IR Colon, pancreatic, breast, ovarian, MM Overexpression 
 PDGFR-α Glioma, glioblastoma, ovarian, HES Overexpression & 
translocation 
 PDGFR-β CMML, glioma, DFSP Translocation  
 c-Kit GIST, seminoma, mastocytosis Point mutations (D816V) 
 Flt-4, Flt3 AML  Internal tandem duplication 
 FGFR1  CML, Stem cell myeloproliferative 
disorder 
Translocation (BCR-, 
FOP-, ZNF198-, CEP110-) 
 FGFR3 MM Translocation & point 
mutations (S249C) 
 FGFR4 Breast, ovary  Overexpression  
 c-Met  Glioblastoma, Colorectal, Hepatocellular 
carcinoma, renal carcinoma, HNSCC 
metastases 
Overexpression, 
translocation (Tpr-), & 
point mutations (Y1253D) 
 RON  Colon, hepatocellular carcinoma Overexpression  
 RET  papillary thyroid carcinoma, MEN2A, 
MEN2B, FMTC & sporadic MTC 
Translocations & point 
mutations 
 ALK Anaplastic large cell lymphoma, lung, 
neuroblastoma 
Translocations (NPM-, 
EML4); point mutations 
CTK  c-SRC Lung, colon, breast & prostate Overexpression, C-
terminal truncation 
 c-YES Lung, colon, breast & prostate Overexpression 
 Abl CML Translocation (Bcr- ) 
 JAK-2  CML, T-ALL, solid Translocation (Tel-), point 
mutation (V617F) 
S/T Kinase  Akt Multiple Overexpression 
 ATM Ataxia telangectasia Point mutations 
 Aurora A & B Multiple Overexpression 
 CDKs Multiple Overexpression 
 mTOR Multiple Overexpression 
 PKCi Non-small cell lung, ovarian Overexpression  
 PLK Multiple Overexpression 
 BRAF Melanoma, thyroid, colon Point mutation (V600E) 
 S6K Multiple Overexpression 
 STK11/LKB1 Peutz-Jeghers syndrome Point mutations 
LK PI3K Prostate, colorectal, breast Overexpression, point 
mutations (H1047R) 
 
Table 2: Summary of kinases mutated in cancer (modified from Zhang et al. 
2009).  RTK: receptor tyrosine kinase, CTK: cytoplasmic tyrosine kinase, S/T Kinase: 
serine/threonine kinase, LK: lipid kinase. MM: Multiple Myeloma; HES: Hypereosinophilic 
Syndrome; CMML: Chronic Myelomonocytic Leukemias; DFSP: Dermatofibrosarcoma 
Protuberans; AML: Acute Myelogenous Leukemia; GIST: Gastrointestinal Stromal tumor; 
HNSCC: Head and neck squamous cell carcinoma; MEN2A: Multiple Endocrine Neoplasia 
type 2A Syndrome; MEN2B: Multiple Endocrine Neoplasia type 2B Syndrome; FTMC: 
Familial Medullary Thyroid Carcinoma; CML: Chronic Myelogenous Leukemia; T-ALL: T 
cell Acute Lymphoblastic Leukemia. 
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 Intensive efforts to survey the kinome across a broad range of tumour 
types for mutations have uncovered a large number of kinases bearing 
mutations, which are currently in the process of being functionally 
characterized (Futreal et al. 2004; Forbes et al. 2005).  
 
 
1.8 Kinase targeting in cancer treatment 
 
 The constitutive activity of kinases in cancer makes them essential for 
survival and/or proliferation of cancer cells. This so-called oncogene addiction 
renders the cancer cell susceptible to the appropriate therapeutic tool able to 
intercept kinase function (Weinstein and Joe 2006).  
 The interest of kinase therapeutic targeting in cancer extends further 
beyond kinases that are directly mutated in cancer cells. Indeed, besides the 
presence of mutations, there are other mechanisms through which kinases, can 
be essential for tumor initiation or growth. In some cases, although not 
oncogenic and not mutated in cancer, some kinases are preferentially required 
for the survival and/or proliferation of the cancer cells. Thus, inhibition of the 
kinase results in a synthetic-lethal phenotype when paired with specific 
mutations present in cancer cells (Kaelin 2005). In some cases, such an 
essential role is explained by the fact that these kinases function in key 
signaling pathways downstream of transforming oncogenes. Examples include 
MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which are located 
in the MAPK pathway and whose inhibition might be synthetic lethal with 
mutation in BRAF (Wang et al. 2007), or mTOR (also known as FRAP1), 
which is located in the PI3K–AKT signaling system (Faivre et al. 2006) and 
whose inhibition might be synthetic lethal with mutations in PI3K or AKT. 
Other examples of this class of targets include kinases that are required to 
sustain rapid proliferation and/or survival in the presence of abnormal ploidy, 
such as the cyclin-dependent kinases (CDKs), which regulate cell cycle 
transition, Aurora kinases, which are essential for accurately dividing 
chromosomes, and Polo-like kinases, which are important during both mitosis 
and cytokinesis (Malumbres and Barbacid 2007). 
 Finally, a third class of kinase targets are those expressed in the tumour 
stroma rather than tumor cells and are required for  tumour formation and 
maintenance. Examples of this category are represented by the vascular 
endothelial growth factor receptor (VEGFR) and the fibroblast growth factor 
receptor (FGFR), which are important in developing and sustaining tumour 
blood supply (Kerbel 2008).  
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There are several possibilities to target therapeutically kinases in cancer; these 
include monoclonal antibodies that can bind to the extracellular domain of the 
kinase, compounds able to favour the proteolytic degradation of the kinase and 
small molecule protein kinase inhibitors (PKI). Monoclonal antibodies have 
had a great success in the case of specific kinases and cancer types, like for 
instance HER2-directed trastuzumab in breast cancer and epidermal growth 
factor receptor (EGFR)-directed cetuximab in colon cancer (Baselga 2006). In 
this dissertation, we have focused in particular on small molecule kinase 
inhibitors. 
 
 
1.9 Small molecule protein kinase inhibitors (PKI) 
 
 Protein kinases are defined by their ability to catalyse the transfer of the 
terminal phosphate of ATP to substrates that usually contain a serine, 
threonine or tyrosine residue. They typically share a conserved arrangement of 
secondary structure elements that are arranged into 12 subdomains that fold 
into a bi-lobed catalytic core with ATP binding in a deep cleft located between 
the 2 lobes (Johnson et al. 1998; Manning et al. 2002; Traxler and Furet 1999). 
ATP binds in the cleft with the adenine ring forming hydrogen bonds with the 
kinase ‘hinge’ — the segment that connects the amino- and carboxy-terminal 
kinase domains. The ribose and triphosphate groups of ATP bind in a 
hydrophilic channel extending to the substrate-binding site that features 
conserved residues that are essential to catalysis. All kinases have a conserved 
activation loop, which is important in regulating kinase activity and is marked 
by conserved DFG and APE motifs at the start and end of the loop, 
respectively. The activation loop can assume a large number of conformations 
with the extremes being a conformer that is catalytically competent and 
usually phosphorylated, and an ‘inactive’ conformer in which the activation 
loop blocks the substrate binding site.  
 Based on this structure, protein kinase inhibitors (PKI) have been 
designed to fit within the kinase domain and block the function of the kinase. 
Most PKIs discovered to date are ATP competitive and present one to three 
hydrogen bonds to the amino acids located in the hinge region of the target 
kinase, thereby mimicking the hydrogen bonds that are normally formed by 
the adenine ring of ATP (Traxler and Furet 1999; Liu and Gray 2006) (Figure 
8). The majority of PKIs do not exploit the ribose-binding site (an exception 
being AZD0530, a novel Src and Abl dual family kinase inhibitor) or the 
triphosphate-binding site of ATP. Overall, protein kinase inhibitors (PKI) are 
classified in: class1, class 2, allosteric and covalent inhibitors. 
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Figure 8: Class 1 and class 2 inhibitors–protein kinase interactions. A. 
The chemical structure depicts hydrophobic regions I and II of ABL1 (shaded 
beige and yellow respectively); hydrogen bonds between the class 1 kinase 
inhibitor (inhibitor atoms engaged in hydrogen bonds to hinge or to allosteric 
site in red) and ABL1 are indicated by dashed lines. B. The DFG-out 
conformation of the activation loop of ABL1 (dark blue) with the type 2 
inhibitor imatinib. The allosteric pocket exposed in the DFG-out conformation 
is indicated by the blue shaded area (modified from Zhang et al. 2009). 
 
 
1.9.1 Type 1 inhibitors 
 
 This class includes the majority of ATP-competitive inhibitors and 
recognizes the so-called active conformation of the kinase (DFG-in) a 
conformation otherwise conducive to phosphotransfer (Liu and Gray 2006) 
(Figure 8A). Most of available kinase inhibitors belong to class 1; this may be 
a consequence of the fact that most compounds were discovered using 
enzymatic assays in which kinases were introduced in their active 
conformation and also of the fact that many kinase inhibitors have been 
synthesized to mimic ATP. Type 1 inhibitors typically consist of a 
heterocyclic ring system that occupies the purine-binding site, where it serves 
as a scaffold for side chains that occupy the adjacent hydrophobic regions I 
and II.  
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1.9.2 Type 2 inhibitors 
 
 Type 2 kinase inhibitors recognize the inactive conformation of the 
kinase (Figure 8B). The conformation that is recognized by type 2 inhibitors 
is referred to as DFG-out, owing to the rearrangement of this motif. Movement 
of the activation loop to the DFG-out conformation exposes an additional 
hydrophobic binding site directly adjacent to the ATP binding site. The 
original discovery that inhibitors such as imatinib and sorafenib bind in the 
type 2 conformation was serendipitous, but subsequent analysis of multiple 
type 2 kinase inhibitor co-crystal structures has revealed that all share a similar 
pharmacophore and exploit a conserved set of hydrogen bonds. Examples of 
type 2 inhibitors that are approved by the US Food and Drug Administration 
include the ABL1, KIT and platelet-derived growth factor receptor (PDGFR) 
inhibitors imatinib and nilotinib (Manley et al. 2005), and the KIT, PDGFR 
and RAF inhibitor sorafenib (Wan et al. 2004). The inhibitor stabilized 
conformational rearrangement of the activation loop observed in type 2 kinase 
inhibitor co-crystal structures demonstrates that the kinase active site is highly 
mobile and can remodel to accommodate a variety of inhibitors (Liu and Gray 
2006).  
 
 
1.9.3 Allosteric inhibitors 
 
The third class of compounds binds outside the ATP-binding site at an 
allosteric site and modulates kinase activity in an allosteric manner. Inhibitors 
belonging to this category exhibit the highest degree of kinase selectivity 
because they exploit binding sites and regulatory mechanisms that are unique 
to a particular kinase. The most well characterized allosteric kinase inhibitor is 
CI-1040, which inhibits MEK1 and MEK2 by occupying a pocket adjacent to 
the ATP binding site (Ohren et al. 2004) (Figure 9). Other examples include: 
GNF2, which binds to the myristate binding site of BCR–ABL1 (Adrián et al. 
2006); the pleckstrin homology domain-dependent Akt inhibitor Akt-I-1 
(Barnett et al. 2005; Lindsley et al. 2005); the IKK (inhibitor of nuclear factor-
κB kinase) inhibitor BMS-345541 (Mclntyre et al. 2003). 
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Figure 9: Allosteric kinase activity modulators. CI-1040 (indicated by a 
blue circle) binds MEK1 (green ribbon) immediately adjacent to the ATP 
binding site (indicated by red circle) (modified from Zhang et al. 2009). 
 
 
More allosteric inhibitors are likely to be uncovered in the future, as a 
greater emphasis is placed on cell-based assays in which kinases are inhibited 
in their native context. This approach presents the advantage of allowing 
compounds to be identified that may require an accessory protein for function. 
For example, the requirement of the mTOR inhibitor rapamycin for the 
intracellular protein FKBP1A would not have been discovered in a 
biochemical mTOR assay.  
 
 
1.9.4 Covalent inhibitors 
 
A fourth class includes kinase inhibitors that are capable of forming an 
irreversible, covalent bond to the kinase active site, most frequently by 
reacting with a nucleophilic cysteine residue (Kwak et al. 2005). The clinically 
most advanced covalent inhibitors are the irreversible kinase inhibitors of the 
epidermal growth factor receptor (EGFR), HKI-272 (Rabindran et al. 2004) 
and CL-387785 (Kobayashi et al. 2005). These two compounds were 
developed to target a relatively specific cysteine residue located at the lip of 
the ATP binding site (Fry et al. 1994).  
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1.10 Mechanisms of resistance to kinase inhibitors (PKI) 
 
 Two major mechanisms have been envisaged to allow cancer cells to 
escape treatment with PKI. Target amplification has been also reported as in 
the case of BCR–ABL1 in CML patients (le Coutre et al. 2000). Owing to the 
rapid proliferation of cancer cells, the acquisition of mutations conferring drug 
resistance has become a recurring theme in the clinic. Indeed, resistance as a 
result of kinase mutations has been documented for inhibitors of BCR–ABL1, 
EGFR, FLT3, KIT and PDGFR (Kobayashi et al. 2005; Roumiantsev et al. 
2002; Fletcher and Rubin 2007; Cools et al. 2004). To date the most extensive 
clinical and laboratory characterization of resistance-causing mutations has 
been performed for BCR–ABL1 in the context of imatinib and second-
generation inhibitors.  
 Alternatively, cancer cells can escape treatment by switching to an 
alternative-signaling pathway that is not inhibited by the PKI (Stommel et al. 
2007). This is the case as an example of the activation of hepatocyte growth 
factor receptor (HGFR/MET) in the acquisition of resistance to EGFR kinase 
inhibitors in lung cancer (Arteaga 2007). 
 Additionally, it has been shown in several haematological tumours that 
quiescent stem cells are refractory to tyrosine kinase inhibitors, and these cell 
populations are probably also involved in resistance mechanisms (Copland et 
al. 2006).  
 As far as mutations in the target, resistance conferred by mutation at the 
gatekeeper residue—so called because the size of the amino acid side chain at 
this position determines the relative accessibility of a hydrophobic pocket 
located adjacent to the ATP binding site (hydrophobic pocket II) —appears to 
be a common mechanism for a variety of kinases. Access to this pocket is 
important to many PKIs because hydrophobic interactions in this site are 
crucial for the binding affinity of the inhibitor. For example, the most 
recalcitrant of the BCR–ABL1 mutants is T315I, which harbours a mutation in 
the gatekeeper residue. Although the gatekeeper residue often comes in close 
contact with type 1 and type 2 ATP binding site inhibitors, it typically does 
not interact with ATP (Liu and Gray 2006). Consequently, mutation of the 
gatekeeper residue generally causes little or no change in kinase activity but 
has the potential to confer inhibitor resistance through a variety of biochemical 
mechanisms. Likewise, mutation of the EGFR T790 residue to methionine 
induces resistance to the quinazoline-based inhibitors gefitinib and erlotinib 
(Pao et al. 2005) by increasing the affinity for ATP, which effectively weakens 
the affinity of ATP-competitive inhibitors. The gatekeeper mutation G697R in 
FLT3 induces resistance to the type 1 staurosporine derivative PKC412 (Cools 
et al. 2004). The gate-keeper mutation in RET (V804M/L) induces resistance 
to vandetanib (Carlomagno et al. 2004). There is currently debate as to 
whether the gatekeeper mutation is pre-existing or acquired following 
inhibitor treatment, though most evidences suggest the mutation pre-exists in a 
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minority of cancer cells, and it is then selected upon PKI treatment. Whatever 
the case, the gatekeeper mutants of BCR–ABL1 (T315I), PDGFRα (T674I), 
EGFR (T790M) and KIT (T670I) are the most frequently reported mutants for 
each of these kinases. This suggests that of design inhibitors that can 
overcome this mutation are urgently needed.  
 
 
1.11 Kinase inhibitors in thyroid cancer: RET inhibitors 
 
 The management of patients with thyroid cancer depends on the 
histological subtype and stage of the tumour. Among thyroid cancers, a great 
majority of WDTC patients can be cured with the conventional treatment 
regimen composed of surgery, radioactive iodine and thyroid hormone therapy 
(Cooper et al. 2009). Less than 10% of WDTC patients present with or 
ultimately develop distant metastases (Durante et al. 2006; Elisei et al. 2010; 
Lee and Soh 2010). Around 40-50% of these subjects are refractory to 
radioactive iodine treatment (Durante et al. 2006; Schlumberger et al. 1996) 
and have a 10-year survival rate of 10-20%. In radioactive iodine resistant 
subjects, conventional chemotherapy response rates are low and long term 
cure is rare (Sherman 2010).  On the other hand, for patients with MTC, which 
comprises around 5% of thyroid cancers, the only curable treatment choice is 
surgery (Schlumberger et al. 2008). For the treatment of ATC, which is the 
least common histologic type of thyroid cancer, surgery, radiotherapy and 
chemotherapy have been used with poor results (Smallridge et al. 2009).  
 Thus, use of PKI has been considered for the treatment of MTC and 
radioiodine-refractory WDTC and ATC. Considering the role of growth factor 
tyrosine kinase signaling pathway in the pathogenesis of thyroid cancers, PKIs 
targeting this pathway, might be a rational choice for treatment (Table 3). 
Randomised clinical trials for several agents are underway and may lead to 
approval of PKIs for thyroid cancer. Some of these inhibitors target RET and 
therefore might be useful in those cancer types, primarily MTC, in which RET 
is involved. These agents are multitargeted and able to inhibit several kinases 
besides RET. Combined action on several targets may have the advantage of 
blocking simultaneously pathways active in both tumor parenchyma and 
stroma (Knight et al. 2010).  
 ZD6474 (vandetanib) is an anilinoquinazoline TKI (Wedge et al. 2002; 
Herbst et al. 2007). ZD6474 docks in the ATP-binding pocket of the RET 
kinase (Knowles et al. 2006) and inhibits RET kinase with an inhibitory 
concentration 50 (IC50) of 100-130 nM (Carlomagno et al. 2002; Herbst et al. 
2007). ZD6474 reduced proliferation and tumorigenicity of fibroblasts 
expressing RET-derived oncogenes (Carlomagno et al. 2002); it was also 
effective in a transplanted mouse model of human MTC (Johanson et al. 2007) 
and in a Drosophila model of RET-mediated tumorigenesis (Vidal et al. 2005). 
ZD6474 shares with certain other RET TKIs (sorafenib, sunitinib, XL-184) the 
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capability of targeting vascular endothelial growth factor receptor type 2 
(VEGFR2/KDR) (IC50 = 38-40 nM), VEGFR3 (Flt-4) (IC50 = 110-260 nM) 
and VEGFR1 (Flt-1) (150 - >1,000 nM) (Wedge et al. 2002; Bianco et al. 
2008). In addition, ZD6474 targets the epidermal growth factor receptor 
(EGFR) (IC50 = 43-500 nM), a kinase that plays a prominent role in epithelial 
cell malignancies (Wedge et al. 2002; Ciardiello et al. 2003; Bianco et al. 
2008). ZD6474 was studied in a Phase III clinical trial in MTC and found to 
be able to prolong progression free survival of MTC patients with respect to 
placebo. Based on these data vandetanib has been FDA approved for the 
treatment of locally advanced or metastatic MTC (Wells et al. 2011). 
 
Table 3: Tyrosine Kinase inhibitors in current trials for thyroid cancer 
and their targets. 
 
Drug Targeted tyrosine kinase 
Axitinib VEGFR1-3, PDGFR, c-Kit 
Lenvatinib (E7080) VEGFR1-3, FGFR1-4, RET, c-Kit, PDGFR 
Motesanib VEGFR1-3, PDGFR, c-Kit, RET 
Pazopanib VEGFR, PDGFR, c-Kit 
Sorafenib VEGFR1-3, PDGFR, RET, RAF, c-Kit 
Sunitinib PDGFR, VEGFR1-3, c-Kit, RET, CSF1R, FLT3 
Vandetanib (ZD6474) VEGFR2-3, RET, EGFR 
 
Abbreviations: CSF1R, macrophage colony-stimulating factor 1 receptor; EGFR, Epidermal 
growth factor receptor; FGFR, Fibroblast growth factor receptor; FLT3, FL cytokine receptor; 
HGFR, Hepatocyte growth factor receptor; PDGFR, Platelet-derived growth factor receptor; 
VEGFR, Vascular endothelial growth factor receptor. 
 
1.12 Kinase inhibitors in thyroid cancer: PLX4032 (Vemurafenib) 
 
 PLX4032 (RG7204, Vemurafenib) is a potent inhibitor of BRAF with 
the V600E mutation. PLX4032 abrogates signaling through the MAP kinase 
pathway, and blocks proliferation of cells carrying BRAF with the V600E 
mutation (Tsai et al. 2008). PLX4032 belongs to a family of mutant BRAF 
kinase inhibitors discovered using a scaffold-based drug design approach. The 
crystallography guided approach allowed optimization of a compound with 
modest preference for the mutated form of BRAF in comparison to wild-type 
BRAF (Figure 10). Preclinical studies showed that BRAF mutant melanoma 
cell strains were highly sensitive to PLX4032 with IC50 in the nM range (60–
450 nM), whereas BRAF wild-type cells were resistant, with IC50 2.4 μM or 
above (Halaban et al. 2010). The biochemical selectivity of vemurafenib 
(PLX4032) translates to cellular selectivity: potent inhibition of ERK 
phosphorylation and cell proliferation occurs exclusively in BRAF-mutant cell 
lines (Yang et al. 2010).  
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 PLX4032 was co-crystallized with a protein construct that contained the 
kinase domain of BRAF (V600E). PLX4032 binds in the active site of one of 
the protomers in the non-crystallographic-symmetry related dimer (Figure 
10). In addition, PLX4032-binding causes an outward shift in the regulatory 
αC helix. The apo-protomer displays the DFG-in conformation with the 
activation loop locked away from the ATP-binding site by a salt-bridge 
between Glu 600 and Lys 507 (Figure 10) (Bollag et al. 2010).  
 
   
Fig. 10: PLX4032 (Vemurafenib). A. Chemical structure of PLX4032. B. 
Structure of the asymmetric dimer of BRAF (V600E) is shown with the 
PLX4032-protomer bound to PLX4032 coloured yellow. The surface outline 
of the other protomer (blue) is shown lightly shaded. Highlighted residues are 
R509 to reflect its role in anchoring the dimer and F595 to show that both 
protomers are in the DFG-in state. The αc-helix shown in magenta is overlaid 
on the PLX4032-bound protomer to show its typical configuration in an 
unoccupied protomer; the binding of PLX4032 causes a shift of the ac-helix as 
noted by the arrow. C. Magnified view of the salt bridge between Lys 507 and 
Glu 600 that helps prevent compound binding to the apo protomer (modified 
from Bollag et al. 2010).  
 
 Clinically, the efficacy and safety of vemurafenib in patients with 
treatment-naive unresectable or metastatic melanoma was studied in a 
randomized open-label phase III trial. Analysis of the data available up to this 
point, showed that after 6 months, overall survival for patients receiving 
vemurafenib was 84%, compared to 64% for patients receiving dacarbazine. 
The estimated median progression-free survival (PFS) was 5.3 months for 
patients receiving vemurafenib, compared to 1.6 months for patients receiving 
dacarbazine (Chapman et al. 2011). Based on these data, in August 2011, 
vemurafenib was approved by the US Food and Drug Administration (FDA) 
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for the treatment of patients with unresectable or metastatic melanoma with 
the BRAFV600E mutation.  
 
1.13 Resistance to PLX4032 
 Current translational research is focusing on understanding mechanisms 
of resistance to vemurafenib and the development of rational combination 
regimens. Different PLX4032-resistant melanoma cell lines showed different 
patterns of ERK and MEK activation, indicating that more than one resistance 
mechanism was involved, and this was confirmed using gene expression 
profiling.  
 Some cell lines showed significant increases in the activation of MAPK 
pathway in some cases explanied by the development of mutations in NRAS 
(Figure 11). A second subset of cell lines showed high levels of the growth 
factor receptor PDGFRβ. These cells have low levels of MAPK pathway 
activity, indicating that tumour cell survival is mediated via switch to an 
alternative signal transduction pathway (Figure 11) (Nazarian et al. 2010). 
 
 
 
 
 
 
Fig. 11: Resistance to vemurafenib can be mediated by MAPK re-activation, 
for instance due to NRAS mutation  (1) or COT activation (2) or to shift to an 
alternative signaling pathway, like for instance activation of PDGFR (3). 
 
 
In another study, a large group of researchers led by Levi Garraway 
and Cory Johannessen at the Broad Institute of Harvard and MIT expressed a 
panel of about 600 human kinases in PLX4032 sensitive melanoma cell lines 
and treated these with the BRAF kinase inhibitor to identify kinases that could 
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confer resistance to the drug. Two kinases, COT and CRAF – both of which 
are members of the Ser/Thr MAP kinase kinase kinase family – were 
highlighted in particular as conferring the most significant resistance in 
multiple cell lines. These kinases are involved in the MAPK pathway, and 
their ability to confer resistance suggests that this is arising through re-
activation of this pathway (Johannessen et al. 2010) (Figure 11). 
 
Taken together, these studies indicate that resistance to this promising 
drug can arise through a variety of mechanisms, some involving downstream 
kinases in the MAPK pathway but none involving secondary mutations in the 
BRAF gene.  
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2. AIMS OF THE STUDY 
 
Mutations in RET (V804 and Y806) causing resistance to RET PKI have been 
described. Mechanisms of thyroid cancer cell resistance to BRAF PKI are still 
unknown. Aims of this study were: 
 
1. To identify RET PKI able to overcome resistance mediated by V804 and 
Y806 RET mutations; 
 
2. To explore mechanisms of resistance to BRAF PKI (vemurafenib) and 
devise strategies to overcome such resistance. 
 
 
 
In addition, this study has been focused on the role of beta-catenin signaling 
pathway in thyroid carcinogenesis and on the functional characterization of a 
novel RET point mutation found in MTC. The resulting manuscripts are 
attached at the end of this Dissertation. 
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3. MATERIALS & METHODS 
 
 
3.1 Compounds 
   Ponatinib (AP24534) was provided by ARIAD Pharmaceuticals Inc, 
(Cambridge, MA, USA). For in vitro experiments, Ponatinib was dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 50 mM. For in vivo 
experiments, it was dissolved in Sodium Citrate, pH - 2.7 and stored at room 
temperature. Vemurafenib (PLX4032) was provided by Roche 
Pharmaceuticals (Nutley, NJ, USA). PLX4032 was dissolved in DMSO at a 
concentration of 50 mM and stored at –80°C. 
 
3.2 Cell Culture 
 
 HEK293 cells were from American Type Culture Collection (ATCC) 
and were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 100 units/ml 
penicillin-streptomycin (GIBCO). Transient transfections were carried out 
with the lipofectamine reagent according to manufacturer's instructions 
(GIBCO). NIH3T3 mouse fibroblasts stably expressing the oncogenic RET 
mutants, associated to sporadic and familial MTC, were grown in DMEM 
supplemented with 5% Calf Serum. TT cells were from American Type 
Culture Collection. TT was derived from the primary tumor of an apparently 
sporadic MTC (Leong et al. 1981). TT harbor a cysteine 634 to tryptophan 
(C634W) exon 11 RET mutation (Carlomagno et al. 1995) as well as a tandem 
duplication of the mutated RET allele (Huang et al. 2003). MZ-CRC-1 cells 
were kindly provided by Robert F. Gagel. MZ-CRC-1 was derived from a 
malignant pleural effusion from a patient with a metastatic MTC (Cooley et al. 
1995). MZ-CRC-1 cells bear a heterozygous (ATG to ACG) transition in RET 
exon 16 resulting in the MEN2B-associated substitution of threonine 918 for 
methionine (M918T). TT cells were grown in RPMI 1640 supplemented with 
16% fetal calf serum (GIBCO, Paisley, PA). MZ-CRC-1 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
calf serum. All media were supplemented with 2 mM L-glutamine and 100 
units/ml penicillin-streptomycin (GIBCO). Human papillary (TPC1, BCPAP) 
and anaplastic (BHT101, SW1736) thyroid cancer cells are described 
elsewhere and were grown in DMEM with 10% Fetal Calf Serum L-glutamine 
and penicillin/streptomycin (Salerno et al. 2011). NTHY (Nthy-ori 3-1) are 
normal human thyrocytes immortalized by the Large T of SV40. NTHY were 
grown in DMEM supplemented with 10% FBS, L-glutamine and 
penicillin/streptomycin. All the cells were SNP genotyped to ensure correct 
identity. 
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3.3 Cell Proliferation Assays 
   5x104 cells were plated in 35-mm dishes. The day after plating, the 
compounds or vehicle were added. Cells were counted in triplicate every day 
for four days and to estimate EC50 value, cells were counted after three days. 
For RNA silencing, the small inhibitor duplex RNAs (siRNA) (ON-target plus 
SMARTpool) siIGF1R were from Dharmacon (Lafayette, CO, USA). The 
siCONTROL Non-targeting Pool (#D-001206-13-05) was used as a negative 
control. Cells were transfected with 100 nM siRNAs using Dharmafect 
reagent following manufacturer’s instructions. The day before transfection, the 
cells were plated in 35 mm dishes at 40% of confluence in RPMI 
supplemented with 4% FBS without antibiotics. Cells were harvested 48 hours 
after transfection.  
 
3.4 Quantitative RT-PCR 
 
 For evaluation of mRNA expression levels, cell lines were grown to 
70% confluency in DMEM with 10% FBS, and then total RNA was extracted 
with RNeasy mini kit (Qiagen) and subjected to on-column DNase digestion 
with the RNase-free DNase set (Qiagen) according to the manufacturer’s 
instructions. Random-primed first strand cDNA was synthesized in a 50 µl 
reaction volume starting from 2 µg RNA by using the GeneAmp RNA PCR 
Core Kit (Applied Biosystems). PCR amplification was performed using the 
GeneAmp RNA PCR Core Kit system starting from 2.5 µl of RT product in a 
reaction volume of 25 µl according to the manufacturer’s instructions. Primers 
were designed by using a software available at http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi and synthesized by 
CEINGE (Naples, Italy). Quantitative (real-time) polymerase chain reactions 
(qRT-PCR) were performed by using the SYBR Green PCR Master mix 
(Applied Biosystems) in the iCycler apparatus (Bio-Rad). Amplification 
reactions (25µl final reaction volume) contained 200 nM of each primer, 3 
mM MgCl2, 300 µM dNTPs, 1x SYBR Green PCR buffer, 0.1U/µl AmpliTaq 
Gold DNA Polymerase, 0.01U/µl Amp Erase, RNase-free water, and 2 µl 
cDNA samples. To verify the absence of non-specific products, 80 cycles of 
melting (55°C for 10 sec) were performed. In all cases, the melting curve 
confirmed that a single product was generated. Amplification was monitored 
by measuring the increase in fluorescence caused by the SYBR-Green binding 
to double-stranded DNA. Fluorescent threshold values were measured in 
triplicate and fold changes were calculated by the ΔΔCt formula: 2-(sample 1 ΔCt - 
sample 2 ΔCt), where ΔCt is the difference between the cycle threshold (Ct) of the 
mRNA of interest and the Ct of the ß-actin mRNA used as housekeeping gene.  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3.5 Protein Studies 
   Immunoblotting experiments were performed according to standard 
procedures. Briefly, cells were harvested in lysis buffer (50 mM Hepes, pH 
7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM 
MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 10 µg of 
aprotinin/ml, 10 µg of leupeptin/ml) and clarified by centrifugation at 10,000 
g. Protein concentration was estimated with a modified Bradford assay (Bio-
Rad). Antigens were revealed by an enhanced chemiluminescence detection 
kit (ECL, Amersham Pharmacia Biotech). Signal intensity was quantified with 
the Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) 
interfaced with the ImageQuant software. Anti-phospho-Shc (#Y317), which 
recognizes Shc proteins when phosphorylated at Y317, was from Upstate 
Biotechnology Inc. Anti-Shc (H-108) was from Santa Cruz Biotechnology. 
Anti-MAPK (#9101) and anti-phospho-MAPK (#9102), specific for 
p44/42MAPK (ERK1/2) phosphorylated at Thr202/Tyr204, were from Cell 
Signaling. Anti-phospho MEK1/2 (#9121), anti-MEK1/2 (#9122), anti-IGF1R, 
anti-phospho-IGF1R, anti-CRAF and anti-phospho-CRAF (serine 338) 
antibodies were from Cell Signaling. Anti-BRAF (sc-9002) was from Santa 
Cruz Biotechnology. Anti-phospho AKT (specific for phosphorylated serine 
473 or threonine 308) and anti-AKT antibodies were from Cell Signaling 
Technology. Anti-RET is a polyclonal antibody raised against the tyrosine 
kinase protein fragment of human RET. Anti-pY905 and anti-pY1062 are 
phospho-specific affinity-purified polyclonal antibodies that recognize RET 
proteins phosphorylated at Y905 and Y1062, respectively. Monoclonal anti-α-
tubulin was from Sigma Chemical Co. Secondary antibodies coupled to 
horseradish peroxidase were from Amersham Pharmacia Biotech.  
 
3.6 Phospho-RTK Arrays 
   The relative levels of tyrosine phosphorylation of receptor tyrosine 
kinases (RTKs) were evaluated with a Human Phospho-RTK array kit (R&D 
Systems, Inc.). Briefly, harvested cells were lysed in NP-40 lysis buffer (1% 
NP-40, 20 mM Tris-HCl pH 8, 137 mM NaCl, 10% Glycerol, 2 mM EDTA, 1 
mM Sodium Orthovanadate, 10 µg/ml Aprotinin, 10 µg/ml Leupeptin) and 
centrifuged at 14,000Xg for 5 minutes at 4°C. For each array, 500 µg of lysate 
were used. Each array contained 42 different anti-RTK antibodies and six 
controls printed in duplicate. Non-specific binding was blocked for 1 hour at 
room temperature on a rocking platform shaker. The lysates were diluted in 
Array Buffer 1 (provided with the kit) and added to each array for overnight 
incubation at 4°C. Freshly diluted detection antibody was added to the arrays 
for 2 hours of room temperature incubation. Phosphorylation levels were 
detected by chemiluminescence (ECL; Amersham Pharmacia Biotech). 
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3.7 In vitro kinase assay 
 
 The in vitro RET auto-phosphorylation assay was performed as 
described elsewhere (Carlomagno et al. 2006). Briefly, subconfluent cells 
were solubilized in lysis buffer without phosphatase inhibitors. Then, 50 µg of 
proteins were immunoprecipitated with anti-RET; immunocomplexes were 
recovered with protein A sepharose beads, washed 5 times with kinase buffer 
and incubated 20 min at room temperature in kinase buffer containing 2.5 µCi 
[γ-32P] ATP and unlabelled ATP to a final concentration of 20 µM. Samples 
were separated by SDS-PAGE. Gels were dried and exposed to 
autoradiography. Signal intensity was analyzed at the Phosphorimager 
(Typhoon 8600) interfaced with the ImageQuant software. 
 
3.8 Chemoinvasion Assay 
 
 In vitro invasiveness through Matrigel was assayed using transwell cell 
culture chambers. Briefly, confluent cell monolayers were harvested with 
trypsin/EDTA and centrifuged at 800Xg for 10 minutes. The cell suspension 
(1X105 cells/well) was added to the upper chamber of transwells on pre-
hydrated polycarbonate membrane filter of 8 µM pore size (Costar) coated 
with 35µg Matrigel (Collaborative Research Inc.). The lower chamber was 
filled with complete medium. Cell dishes were incubated at 37 °C in 5% CO2 
for 24h. Non-migrating cells on the upper side of the filter were wiped-off and 
migrating cells on the reverse side of the filter were stained with 0.1% crystal 
violet in 20% methanol for 15 minutes, counted and photographed. 
 
3.9 Wound Healing Assay 
 
 A wound was inflicted on the confluent monolayer cells by scraping a 
gap using a micropipette tip. Photographs were taken at 100X magnification 
using phase-contrast microscopy immediately after wound incision and 12 
hours later to assess whether cells had migrated into the wound. 
 
3.10 Statistical Analysis 
 
 Two-tailed paired Student’s t test (normal distributions and equal 
variances) was used for statistical analysis. Differences were significant when 
P < 0.05. Statistical analysis to estimate EC50 value was performed using the 
Graph Pad Prism and InStat software program (version 3.06.3, San Diego, CA, 
USA). 
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4. RESULTS 
 
 
4.1 PONATINIB IS A NOVEL RET TKI ABLE TO OVERCOME RET 
GATE-KEEPER MUTATION MEDIATED RESISTANCE 
 
 
4.1.1 Ponatinib efficiently inhibits RET kinase function. 
 
 Several RET kinase inhibitors (PKI) have been identified and one of 
them, vandetanib (ZD6474) was recently approved for the treatment of 
medullary thyroid carcinoma (MTC) (Santoro et al. 2006; Wells et al. 2009; 
Sherman 2011; Wells et al. 2011). However, RET mutations have been proved 
to mediate resistance to vandetanib. Indeed, we have previously reported that 
RET mutants in the V804 residue, naturally occurring in MTC patients, are 
refractory to inhibition by vandetanib and by pyrazolo-pirimidines of the PP 
series (Carlomagno et al. 2004). At the structural level, this was caused by the 
particular position that V804 occupies in the RET kinase domain; indeed, 
V804 is the gate-keeper position, corresponding to T315 in ABL, at the 
entrance (gate) of the RET ATP binding pocket. Therefore, its replacement 
with bulky residues such as methionine or leucine, as it occurs in these 
mutants, impairs drug binding (Knowles et al. 2006). Also mutations targeting 
nearby residue Y806 strongly impair drug binding to the RET kinase 
(Carlomagno et al. 2009). Both V804 (to leucine or methionine) and, though 
very rarely, Y806 (to cysteine) mutations have been found in patients affected 
by MTC, thus raising the possibility that they may mediate a primary 
resistance to the treatment. It may also be envisaged that, should these 
mutations occur during treatment, they can also mediate a secondary 
(acquired) resistance. Therefore, it is important to isolate novel RET PKI that 
may overcome such resistance mechanisms.  
 Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that 
potently inhibits native and mutant BCR-ABL at clinically achievable drug 
levels. Ponatinib also has in vitro inhibitory activity against a discrete set of 
kinases, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), 
and platelet derived growth factor receptor α (PDGFRα) (Gozgit et al. 2011; 
Zhou et al. 2011; Huang et al. 2010; O'Hare et al. 2009). Importantly, 
ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including 
T315I mutant in the gate-keeper residue (corresponding to RET V804). 
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 Thus, we sought to check whether ponatinib had activity against RET 
and its oncogenic variants, including those causing resistance to other PKIs. 
We initially studied whether ponatinib (AP24534) was able to inhibit in vitro 
RET enzymatic activity (Carlomagno et al. 2006). To this aim, HEK293 cells 
were transiently transfected with myc-tagged RET/C634R, an oncogenic RET 
mutant associated to MTC (Wells et al. 2009). RET protein was 
immunoprecipitated at room temperature in kinase buffer containing 2.5 µCi 
[γ-32P] ATP. Samples were separated by SDS-PAGE; gels were dried and 
exposed to Phosphorimager to measure extent of RET protein auto-
phosphorylation. The average results of three independent assays showed that 
IC50 of ponatinib for RET/C634R was 25 nM (95% confidence intervals 
23.15 to 28.77) (Figure 12). 
 
 
 
 
Fig. 12: Ponatinib inhibits in vitro RET autophosphorylation at 
nanomolar range doses. RET/C634R was immunoprecipitated and 
immunocomplexes were incubated in kinase buffer containing 2.5 µCi [γ-32P] 
ATP and different doses of ponatinib. Samples were separated by SDS-PAGE; 
gels were dried and exposed to Phosphorimager to measure extent of RET 
protein auto-phosphorylation. The average results of three independent assays 
are reported as % RET kinase activity with respect to vehicle-treated 
immunocomplexes by using the Graphpad software. 
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Then, we verified whether ponatinib had activity against vandetanib-resistant 
RET mutants. HEK293 cells were transfected with RET/V804M; RET protein 
was immunoprecipitated and immunocomplexes were incubated in kinase 
buffer containing 2.5 µCi [γ-32P] ATP. Samples were separated by SDS-PAGE 
and dried gels were exposed to Phosphorimager. The average results of three 
independent assays showed that IC50 of ponatinib for RET/V804M was 33 
nM (95% confidence intervals 26.41 to 43.58), thus quite similar to that 
observed for the C634R mutant (Figure 13). 
 
 
 
Fig. 13: Ponatinib inhibits in vitro autophosphorylation of RET mutant in 
the V804 gate-keeper position. RET/V804M was immunoprecipitated and 
immunocomplexes were incubated in kinase buffer containing 2.5 µCi [γ-32P] 
ATP and different doses of ponatinib. Samples were separated by SDS-PAGE; 
gels were dried and exposed to Phosphorimager to measure extent of RET 
protein auto-phosphorylation. The average results of three independent assays 
are reported as % RET kinase activity with respect to vehicle-treated 
immunocomplexes by using the Graphpad software. 
 
 
 Overall, these findings prove that ponatinib is a potent RET kinase 
PKI, effective also against RET mutants in the gate-keeper residue. 
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4.1.2 Ponatinib efficiently inhibits RET oncoprotein phosphorylation in 
intact cells. 
 
 We sought to verify whether ponatinib activity against RET enzyme in 
vitro translated into an efficient reduction of phosphorylation and signaling of 
various RET mutants in intact cells. To this aim, RET point mutants depicted 
in Figure 14 were selected (RET mutation database at 
www.arup.utah.edu/database/MEN2/MEN2_welcome.php or 
www.sanger.ac.uk/genetics/CGP/cosmic/). All these mutants have been 
associated to MTC familial cases (MEN2), sporadic or both (Waguespack et 
al. 2011). Of particular note are C634 and M918T mutants, those most 
frequently found in MEN2A or MEN2B, respectively. M918T is also the most 
prevalent RET mutant in sporadic MTC. Mutant A883 is found in the few 
MEN2B patients negative for M918T. V804 mutants (either to methionine or 
leucine), as well as Y806 mutant were also tested. 
 
- 
 
Fig. 14: Schematic representation of the RET mutants tested in this study.  
 
 
 HEK293 cells were transiently transfected with the various RET 
constructs and after 24 hours cells were treated with ponatinib at various doses 
for 60 min and harvested. RET phosphorylation was measured at two sites 
(Y905, the autocatalytic tyrosine and Y1062 the multidocking site) by 
immunoblot with phospho-specific antibodies (Salvatore et al. 2000). 
Phosphorylation of SHC, a RET substrate, was studied as well (Borrello et al. 
1994). Though with some variability, ponatinib IC50 for the phosphorylation 
of the various RET mutants was confirmed to be 10-50 nM (Figures 15-24). 
Again, importantly, ponatinib was effective (though slightly less than the other 
mutants) also against RET mutants in V804, the gatekeeper residue and in the 
nearby Y806 residue. In these cases, ponatinib IC50 was about 50 nM. All 
together, these data indicate that ponatinib is a potent inhibitor of a large set of 
oncogenic RET mutants, including those bearing mutations in the gate-keeper 
residue. 
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Fig. 15: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
C634 position. HEK293 cells transiently transfected with indicated RET 
mutant were treated with indicated doses of compound for 60 min. Proteins 
were harvested and RET and SHC phosphorylation assessed by immunoblot. 
Total RET levels are shown for normalization. 
 
 
 
 
Fig. 16: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
M918 position. For a description, see legend to Figure 15 
 
 
 
Fig. 17: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
E768 position. For a description, see legend to Figure 15 
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Fig. 18: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
L790 position. For a description, see legend to Figure 15 
 
 
 
 
Fig. 19: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
L790 position. For a description, see legend to Figure 15 
 
 
 
 
Fig. 20: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
Y791 position. For a description, see legend to Figure 15 
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Fig. 21: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
V804 position (V804L). For a description, see legend to Figure 15 
 
 
 
Fig. 22: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
V804 position (V804M). For a description, see legend to Figure 15 
 
 
 
Fig. 23: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
Y806 position. For a description, see legend to Figure 15 
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Fig. 24: Ponatinib inhibits in vivo phosphorylation of RET mutant in 
A883 position. For a description, see legend to Figure 15 
 
4.1.3 Ponatinib efficiently inhibits RET-mediated cancer cell 
proliferation. 
 
 Then, we asked whether ponatinib-mediated RET kinase inhibition was 
translated into cell proliferation blockade. To this aim, growth curves were 
performed by using different doses of compound and NIH3T3 transfectants 
expressing RET/C634R or RET/M918T mutants. As control, we used 
HRAS/G12V-transformed or untransfected NIH3T3 cells. Growth curves 
reported in Figures 25-28 demonstrate that ponatinib blunted cell proliferation 
at nM concentration and that this effect was RET-dependent, as it was more 
intense in cells expressing RET than RET-negative cells. 
 
 
 
 
Fig. 25: Ponatinib inhibits proliferation of NIH3T3 cells transformed by 
RET/C634R. Cells were plated in triplicate, treated with indicated doses of 
ponatinib (NT: not treated) and counted at different time points. Average 
results of 3 independent determinations are reported ± S.D. 
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Fig. 26: Ponatinib inhibits proliferation of NIH3T3 cells transformed by 
RET/M918T. Cells were plated in triplicate, treated with indicated doses of 
ponatinib (NT: not treated) and counted at different time points. Average 
results of 3 independent determinations are reported ± S.D. 
 
 
 
 
Fig. 27: Ponatinib exerts only mild proliferative inhibition of NIH3T3 
cells transformed by HRAS. Cells were plated in triplicate, treated with 
indicated doses of ponatinib (NT: not treated) and counted at different time 
points. Average results of 3 independent determinations are reported ± S.D. 
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Fig. 28: Ponatinib exerts only mild proliferative inhibition of wild type 
NIH3T3 cells. Cells were plated in triplicate, treated with indicated doses of 
ponatinib (NT: not treated) and counted at different time points. Average 
results of 3 independent determinations are reported ± S.D. 
 
Finally, we measured proliferative effects of ponatinib on thyroid 
cancer cells endogenously expressing RET mutants. We selected TT cells 
(MTC harbouring C634W RET mutation) and TPC1 cells (PTC cells 
harbouring RET/PTC1 chimeric oncogene); as control, we used BCPAP (PTC 
cell line harbouring BRAF V600E mutation and no RET mutation) and Nthy-
ori 3-1, normal thyrocytes immortalized by Large T SV40. Figures 29-32 
show that ponatinib had potent anti-proliferative effects in RET-positive 
cancer cells. In TT cells, effects were seen at doses (1-5 nM) even smaller than 
IC50 for RET kinase (10 nM), suggesting that targets other than RET can 
contribute to such a potent growth inhibitory activity or that MTC cells are 
highly susceptible even to minor reduction of RET kinase activity.  
 
 
 
Fig. 29: Ponatinib inhibits proliferation of RET/C634W-positive TT cells. 
Cells were plated in triplicate, treated with indicated doses of ponatinib (NT: 
not treated) and counted at different time points. Average results of 3 
independent determinations are reported ± S.D. 
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Fig. 30: Ponatinib inhibits proliferation of RET/PTC1-positive TPC1 
cells. Cells were plated in triplicate, treated with indicated doses of ponatinib 
(NT: not treated) and counted at different time points. Average results of 3 
independent determinations are reported ± S.D. 
 
 
 
Fig. 31: Ponatinib exerts only mild proliferative inhibition of 
BRAF/V600E (RET wild type) BCPAP cells. Cells were plated in triplicate, 
treated with indicated doses of ponatinib (NT: not treated) and counted at 
different time points. Average results of 3 independent determinations are 
reported ± S.D. 
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Fig. 32: Ponatinib exerts only mild proliferative inhibition of SV40-LT-
immortalized (RET wild type) normal thyrocytes. Cells were plated in 
triplicate, treated with indicated doses of ponatinib (NT: not treated) and 
counted at different time points. Average results of 3 independent 
determinations are reported ± S.D. 
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4.1.4 Ponatinib efficiently inhibits RET-mediated tumor growth in 
mouse xenografts. 
 
 Finally, we sought to determine whether ponatinib had inhibitory 
effects in vivo against RET-dependent tumor growth. To this aim, we injected 
nude mice with 5x107 TT cells. After approximately 30 days, when tumors 
measured ∼70-100 mm3, animals (10 for each group) were randomly assigned 
to receive per os ponatinib (30 mg/kg/day) or vehicle 5 days/week for three 
weeks. Tumor size was monitored with calipers initially every 7 days and then 
every 3 days. Treatment with ponatinib strongly reduced tumor growth 
(Figure 33). Mice were sacrificed after 3 weeks, when tumors in vehicle 
treated mice were very large while in most ponatinib-treated mice they were 
virtually undetectable. Importantly, we noted no sign of wasting in treated 
mice. 
 
 
 
 
Fig. 33: Ponatinib exerts potent anti-tumorigenic activity in nu/nu mice 
xenografted with TT cells.  
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4.2 ISOLATION OF PLX4032 RESISTANT THYROID CANCER 
CELLS AND CHARACTERIZATION OF THE MECHANISMS OF 
RESISTANCE. 
4.2.1 Chronic BRAF Inhibition leads to Acquired Drug Resistance 
 
 We have previosuly reported that vemurafenib (PLX4032) was able to 
reduce proliferation of BRAF mutant thyroid cancer cells in culture (Salerno 
et al. 2010). To investigate if chronic BRAF inhibition could lead to drug 
resistance, a panel of thyroid cancer cell lines harboring the V600E mutation 
in the BRAF gene [BCPAP (V600E/V600E) (PTC), BHT101 (WT/V600E) 
(ATC) and SW1736 (WT/V600E) (ATC)], were chronically treated with 
increasing concentrations of PLX4032 (Figure 34). This was done following 
two different protocols: 
(i) Parental cells were treated with step-by-step increased PLX4032 
concentration starting from 100 nM up to 2µM (method R1); 
(ii) Parental cells were initially treated with high dose (5µM) of PLX4032 
for 12 hrs, and then subjected to scaling-up, starting from 100nM to 
reach 2µM in a step-wise manner (method R2). 
 
 
 
 
Fig. 34: Schematic representation of generation of PLX4032 resistant 
cells. 
 
Both methods, successfully allowed us to get resistant sub-lines (R1 & 
R2) able to grow at 2μM of PLX4032. Since, the PLX4032 resistant cells R1 
and R2 did not behave differently, we selected BCPAP-R1, BHT101-R1 and 
SW1736-R1 cells for further experiments. 
 Treatment of parental cells (BCPAP-P, BHT101-P & SW1736-P) with 
PLX4032 reduced viability with Inhibitory Concentrations 50 (IC50) of about 
500 nM (IC50; BCPAP-P = 444nM, BHT101-P = 240nM & SW1736-P = 
400nM). Noteworthy, significantly higher doses of PLX4032 were required to 
achieve 50% growth inhibition in resistant cells (IC50; BCPAP-R = >5μM, 
BHT101-R = 2.9μM & SW1736-R = > 5μM), (Figure 35). These data 
demonstrate that chronic treatment with a specific BRAF inhibitor can lead to 
development of resistance in thyroid carcinoma harboring BRAF V600E 
mutation.  
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Fig. 35: BRAF mutant cell lines chronically treated with PLX4032 
develop drug resistance. Sensitivity of parental (IC50 200 – 450nM) and 
corresponding resistant cells (IC50 > 3-5 μM) to PLX4032 by proliferation 
assay. Cells were exposed to different doses of compound for 72 hr and then 
counted in triplicate: data are reported as % of cell number. Sensitivity of 
parental and resistant cells was significantly different (p < 0.001) at dose 1 
μM. 
 
 All parental and resistant cells were genotyped by sequencing the 15th 
exon of BRAF using Sanger’s method. The sequencing result confirmed the 
presence of BRAF V600E mutation in parental cells and that this mutation 
was kept in resistant cells, as well (Figure 36).  
 
 
 
 
 
Fig. 36: BRAF V600E mutation in parental and PLX4032-resistant 
thyroid carcinoma cell lines.  
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Altogether, these findings demonstrate that thyroid cancer cells can develop 
resistance to PLX4032 while keeping the BRAF V600E mutation. 
 
 
4.2.2 PLX4032-resistant cells feature increased migration and motility  
 
 To characterize the phenotype of PLX4032-resistant thyroid carcinoma 
cells, we investigated proliferation, invasion through Matrigel and motility. No 
significant differences were noted in the growth rate between parental and 
resistant cells (data not shown). In contrast, resistant cells featured increased 
invasion through Matrigel (Figure 37) and increased motility on the plastic 
dish (Figure 38). Moreover, while parental cell motility and invasion were 
sensitive to PLX4032 treatment, as expected, resistant cells were refractory to 
the treatment.  
 
 
 
Fig. 37: PLX4032-resistant cells display increased invasion through 
Matrigel. Cells were seeded in upper chamber of transwells coated with 
Matrigel and incubated for 12 h in the presence or not of PLX4032 (1μM); the 
upper surface of the filter was wiped clean, and cells on the lower surface 
were stained and counted. Invasive ability was expressed as number of 
invaded cells. Values represent the average of triplicate experiments ± SD. **, 
P < 0.001. Note that resistant cells display increased invasion with respect to 
parental cells and that such invasion, differently from parental cells, does not 
respond to PLX4032 treatment. 
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Fig. 38: PLX4032-resistant cells display increased motility. Wound healing 
assay: cells were plated at confluence and scratch wounds were inflicted. After 
24h (with cells treated or not with PLX4032 1μM), cell plates were 
photographed and cells closing the wound were counted. Wound closure was 
measured by calculating pixel densities in the wound area and expressed as 
percentage of wound closure of triplicate areas ± SD. The avearage results of 
three experiments are reported with bars representing 95% confidence 
intervals; (**, p < 0.001). Note that resistant cells display increased motility 
with respect to parental cells and that such motility, differently from parental 
cells, does not respond to PLX4032 treatment. 
 
 
 Altogether, these findings demonstrate that thyroid cancer cells 
resistant to PLX4032 acquired a more malignant phenotype, that is 
characterized by increased motility and invasion. 
 
 
 
 
 
 
 
 
55 
 
4.2.3 PLX4032-resistant cells feature altered intracellular signaling  
 
To investigate the mechanisms of PLX4032-resistance in vitro, we 
used phosphospecific antibodies to probe the activation status of the RAF 
downstream effectors, MEK1/2 and ERK1/2, in parental versus resistant cells, 
with and without PLX4032 (Figure 39). 
 
 
 
 
Fig. 39: PLX4032-resistant cells display differential ERK activation. 
Parental and PLX4032-resistant cells were treated with PLX4032 (1μM) and 
the effects on ERK signaling were determined by immunoblotting for 
pMEK1/2 and pERK1/2 levels. Total MEK1/2, ERK1/2 and tubulin levels are 
reported as loading controls. 
 
 
 As expected, PLX4032 decreased pMEK1/2 and pERK1/2 in all 
parental cells (P). As far as resistant cells (R), the pattern of MEK-ERK 
phosphorylation varied among resistant cells, suggesting distinct mechanisms. 
BCPAP-R showed strong resistance to PLX4032-induced MEK/ERK 
inhibition (suggesting MAPK pathway reactivation). Instead, BHT101-R 
(totally) and SW1736-R (partially) remained sensitive to PLX4032-mediated 
decrease in the levels of p-MEK1/2 and p-ERK1/2 (suggesting bypass through 
an alternative signaling pathway). 
To search for the mechanism of pMEK resistance in BCPAP-R, we 
observed that PLX4032-resistant cells featured increased levels of 
phosphorylation of CRAF at 338 site, a marker of CRAF activation (Figure 
40). This was not observed in BHT101 and SW1736 resistant cells (data not 
shown). CRAF activation in BCPAP-R could be a suitable explanation of 
pMEK/pERK resistance to PLX4032 treatment and of to the growth, invasion 
and motility inhibitory effects of the drug (see also below). The molecular 
mechanism for CRAF phsophorylation remains unclear. By Sanger 
sequencing we excluded mutations in RAS that can favour the formation of 
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BRAF/CRAF heterodimers; we also excluded secondary mutations in BRAF 
that can impair drug binding (data not shown) 
 
 
 
Fig. 40: PLX4032-resistant BCPAP-R feature CRAF phosphorylation. 
Parental and PLX4032-resistant cells were treated with PLX4032 (1μM) and 
the effects on BRAF and CRAF signaling were determined by immunoblotting 
for pCRAF (S338) phosphorylation levels. Total CRAF, BRAF and tubulin 
levels: loading controls. 
 
 
Whatever the mechanism, we checked whether MEK inhibitors could 
overcome PLX4032 resistance; this was particularly important for BCPAP-R 
cells in which we showed that resistance to PLX4032 was accompanied by 
inability of PLX4032 of reducing pMEK. As a control, we initially showed 
that U0126 was able to block pERK as expected (Figure 41).  
 
 
 
 
Fig. 41: Effects of MEK inhibitor (UO126). Immunoblots showing pERK 
levels in parental and resistant cells treated with DMSO (NT) or 10 μM U0126 
for 1 h.  
 
 
Thereafter, we checked cell growth inhibition by U0126. Noteworthy, 
the three resistant cell lines (including BCPAP-R) were quite resistant not only 
to PLX4032 but also to U0126 (IC50 increased from 3.9 to almost 6.2 μM), 
consistent with a model whereby these resistant cells have switched from 
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BRAF-ERK to a compensatory pathway for proliferation (Figure 42). This 
applied also to BCPAP-R cells; therefore also for these cells resistance cannot 
be explained by the observed pMEK rescue through CRAF. 
 
 
 
 
Fig. 42: Effects of MEK inhibitor (UO126). Proliferation curves for parental 
and resistant cells treated with the indicated UO126 for 96 h (relative to 
DMSO-treated controls). 
 
 
4.2.4 AKT pathway activation in PLX4032-resistant cells. 
 
By searching for alternative pathway activation that may mediate 
resistance, we found that all the three resistant cells featured up regulation of 
pAKT (Ser473) (site of phosphorylation by TORC2/PDK2 complex) (Figure 
43). 
 
 
 
 
Fig. 43: AKT pathway upregulation in PLX4032-resistant cells. Cells were 
treated with PLX4032 (1μM) and the effects on AKT signaling were 
determined by immunoblotting for pAKT (Ser473) levels. Total AKT and 
tubulin levels: loading controls. 
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There were however differences among the resistant cells, with 
BCPAP-R and SW1736-R featuring constitutive potentiation of pAKT 
(Ser473). Instead, BHT-101-R featured only a modest baseline potentiation of 
pAKT (Ser473), but AKT phospho-levels strongly increased upon PLX4032 
treatment.  
Moreover, in BCPAP-R and SW1736-R resistant cells, increased AKT 
phosphorylation also observed at the residue Thr308 (PDK1 site), which 
indicates activation of some upstream signaling event (as examples: RTK or 
PI3K activation, PTEN loss). We did not observe the same feature in 
BHT101-R (Figure 44). 
 
 
 
 
 
 
Fig. 44: AKT pathway upregulation in PLX4032-resistant cells. Cells were 
treated with PLX4032 (1μM) and the effects on AKT signaling were 
determined by immunoblotting for pAKT (T308). Total AKT and tubulin 
levels: loading controls. 
 
 Thus, we checked sensitivity of PLX4032-resistant cells to PI103, a 
double PI3Kα and mTOR inhibitor to study the relevance of the 
PI3K/AKT/mTOR cascade in mediating resistance. Growth of both parental 
and resistant cells was equally inhibited (Figure 45). This indicates that 
inhibition of AKT pathway can overcome the PLX4032 resistance. 
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Fig. 45: Compensatory signaling inhibition limits the growth of PLX4032 
resistant cells. Proliferation curves of parental and resistant cells treated with 
the indicated PI103 concentrations for 96 h (relative to DMSO-treated 
controls). 
 
 
One possibility to explain AKT pathway activation was 
downregulation of the PTEN phosphatase, a negative regulator of AKT 
phosphorylation. However, PTEN altered expression was excluded by Q-RT-
PCR (data not shown).  
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5. DISCUSSION 
 
 This dissertation is focused on the study of molecular targeted 
therapeutic approaches for thyroid cancer and, in particular, on mechanisms of 
resistance to molecular targeting of BRAF and RET kinases.  
 Most well-differentiated thyroid carcinomas (PTC and FTC) are 
effectively treated by surgery, adjuvant radio-iodine ablation and TSH 
suppression. In contrast, there is a urgent need of novel therapeutic measures 
for thyroid carcinomas that have lost radio-iodine concentration ability (PDTC 
and ATC) as well as for MTC, a neuroendocrine cancer deriving from C-cells 
that do not express sodium-iodine symporter (NIS) (Cooper et al. 2009; 
Schlumberger et al. 2008).  
 PTC often features oncogenic activation of BRAF serine/threonine 
kinase and MTC is associated to oncogenic conversion of RET tyrosine kinase 
(Nikiforov et al. 2011). BRAF mutation (most commonly V600E) is found in 
about half PTC and one third of ATC. Though still quite controversial, 
correlative studies in human patients have suggested that PTC with aggressive 
features (including large tumor size, distant metastases, development of radio-
iodine refractory disease, recurrence) are commonly associated to BRAF 
mutation (Xing 2007). Importantly, experimental models have supported this 
concept by demonstrating that BRAF is able to stimulate the expression of 
genes involved in invasion and metastatic dissemination and to obstruct 
markers of thyroid differentiation (Nucera et al. 2010; Mesa et al. 2006). One 
mechanism by which BRAF-driven constitutive MAPK pathway activation 
inhibits NIS expression is based on a TGF-β autocrine loop, which 
downregulates Pax8 and evokes a Smad3-dependent inhibition of Pax8 
binding to the NIS promoter (Riesco-Eizaguirre et al. 2009). Consistently, 
transgenic mice featuring thyroid targeted expression of BRAF V600E were 
shown to develop PTC rapidly evolving to poorly-differentiated carcinomas 
and BRAF pathway blockade was demonstrated to restore thyroid 
differentiation and radio-iodine uptake in this mouse model (Knauf et al. 2005; 
Chakravarty et al. 2011).  
 MTC is associated to RET mutation in about half of sporadic cases and 
virtually all familial cases and RET mutation, particularly M918T was 
demonstrated to correlate with an aggressive clinical behaviour (Elisei et al. 
2008). 
 Oncogenic kinases like RET and BRAF can be targeted with small 
molecule organic compounds (PKI) that by binding the ATP pocket (Type 1 
and Type 2 inhibitors) can obstruct kinase function and induce cancer cell 
death or proliferative arrest (Sherman 2011). Several RET and BRAF  PKIs 
have been identified and their efficacy studied in preclinical models and in 
some cases in clinical trials. The most advanced RET PKIs, are vandetanib 
and cabozantinib (XL184); these compounds target RET as well as other 
receptors including VEGFR (in the case of both) and EGFR (in the case of 
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vandetanib) and therefore are able to exert their effects on several targets in 
tumor cells and tumor stroma (Wells et al. 2011; Kurzrock et al. 2011). One 
BRAF PKI, vemurafenib (PLX4032), has been demonstrated to exert activity 
in preclinical models of thyroid cancer (Salerno et al. 2010; Xing et al. 2011; 
Nucera et al. 2009; Nucera et al. 2010; Nehs et al. 2010). Vemurafenib 
recently elicited spectacular clinical regressions of the disease in the large 
majority of metastatic melanoma patients, which were positive for BRAF 
mutation (Bollag et al. 2010; Chapman et al. 2011). 
 It is well-established that cancers can escape treatment with PKIs by 
acquiring resistance and two paradigms of molecular resistance formation 
have been depicted. In one case, cancer cells develop secondary mutations in 
the protein kinase that is targeted by the drug, impairing drug binding. In the 
second case, cancer cells feature activation of compensatory signaling 
pathway that bypass the drug-elicited block.  
 The first model is illustrated by the development of resistance to 
imatinib (Gleevec) in CML patients secondary to the development of point 
mutations in BCR-ABL that, either directly block drug binding or 
allosterically change the conformation of the kinase to which imatinib binds. 
Among these mutations, T315I mutation affecting the so-called gate-keeper 
residue is the most commonly found and revealed to be the most difficult to 
deal with. Importantly, mutations in corresponding residues have been found 
to mediate resistance of oncogenic kinases other than BCR-ABL to their 
corresponding PKIs, including T790M for EGFR, T670I for KIT, T674I for 
PDGFRα and T681I for PDGFRβ (Druker 2006). RET mutations in the gate-
keeper residue (V804M, V804L) have been demonstrated to cause resistance 
to vandetanib and though these mutations have not been yet described as 
secondary mutations developed upon treatment with the drug, they are 
pathogenetic mutations causing MTC and they are particularly prevalent in 
some geographic areas including Italy (Pinna et al. 2007; Romei et al. 2010). 
Thus far, mutations in BRAF have not been described to cause resistance to 
BRAF PKIs (Poulikakos et al. 2011). 
 The second model is illustrated by resistance formation to EGFR family 
PKIs that involved the up-regulation of alternative receptors, like MET and 
PDGFR, ultimately leading to rescue of cancer cell growth (Sergina et al. 
2007; Stommel et al. 2007). Often such a switch involved activation of the 
PI3K/AKT signaling cascade, a pathway that is commonly involved in cancer 
cell treatment resistance (Villanueva et al. 2010; Paraiso et al. 2011). 
Recently, molecular mechanisms of resistance to BRAF PKI in melanoma 
cells have been identified and they fit with this second model. Indeed, 
melanoma cells resistant to BRAF blockade either developed activation of 
NRAS and COT kinase, or activation of PDGFR. Activation of NRAS or COT 
bypassed BRAF block sustaining MAPK signaling via CRAF or MEK, 
respectively. Instead, PDGFR activation likely sustained cell proliferation by 
stimulating pathways alternative to the MAPK one (Solit et al. 2010; Nazarian 
et al. 2010; Johannessen et al. 2010; Poulikakos et al. 2011). 
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 In this framework, this Dissertation has been focused on RET and BRAF 
PKI with a view of exploring mechanisms of resistance and possible strategies 
to overcome it. Specifically, since it is known that some RET mutations confer 
resistance to PKIs, in a first part of the Dissertation we have looked at 
compounds able to function against these RET mutants; in the second part of 
the work, since no information is currently available about resistance of 
thyroid cancer cells to BRAF PKIs, we have isolated and studied cells 
resistant to vemurafenib. 
 As far as RET, here we provide evidence that ponatinib (AP24534) is a 
novel RET PKI. Ponatinib is a multitargeted Type 2 kinase inhibitor that 
inhibits a set of kinases, including BCR-ABL, FLT3, KIT, FGFR1, and 
PDGFRα at clinically achievable drug levels (Gozgit et al. 2011; Zhou et al. 
2011; Huang et al. 2010; O'Hare et al. 2009). Prompted by the observation that 
ponatinib inhibits also T315I BCR-ABL (O'Hare et al. 2009), we explored 
activity of this compound against RET and RET (V804 and Y806) drug-
resistant mutants. We show that ponatinib is a potent RET PKI, with 
nanomolar activity in RET phosphorylation assays (IC50: 10-50 nM). 
Ponatinib inhibited RET-driven proliferation of fibroblasts transformed by 
RET derived oncogenes and also the proliferation of thyroid carcinoma cells 
(both PTC and MTC) bearing RET-derived (RET/PTC and RET/MEN2) 
oncogenes. Finally, ponatinib significantly reduced growth of MTC cells (TT) 
tumor xenografts in nude mice. However, it is possible that inhibition of 
multiple targets besides RET can concur to these in vitro and in vivo anti-
neoplastic effects. This is supported by the observation that inhibition of MTC 
cell proliferation in vitro was noted at doses even smaller that IC50 for the 
RET kinase, suggesting that the drug was probably acting on multiple targets. 
Importantly, ponatinib was effective also against V804 and Y806 RET 
mutants at doses only slightly higher than those required to inhibit the other 
RET mutants tested. This raises the possibility that this drug may be useful for 
MTC patients bearing such RET mutations. We and other have previously 
reported that sorafenib was active against RET V804 (Carlomagno et al. 2006; 
Plaza-Menacho et al. 2007); however, this drug did not achieve very potent 
results in a small Phase II study in MTC patients (Lam et al. 2010). Being 
ponatinib in adavanced clinical experimentation in patients affected by 
leukemia, overall, our data suggest that this drug may be worth testing also in 
patients affected by MTC who failed previous treatments. 
 As far as BRAF targeting, PLX4032 (vemurafenib) was previously 
reported to have cytostatic and anti-tumorigenic activity against thyroid cancer 
cells, but no mechanism of resistance was previosuly known. Thus, we started 
by selecting BRAF mutant thyroid cancer cells (both PTC- and ATC-derived) 
able to proliferate also in the presence of PLX4032 (2 uM concentration). 
According to what has been observed in melanoma, PLX4032-resistant 
thyroid cancer cells did not feature secondary BRAF mutation in the gate-
keeper residue (data not shown), thus pointing to pathway switch as a likely 
mechanism of resistance. Two out of the three PLX4032-resistant cells were 
63 
 
still susceptible to PLX4032-mediated inhibition of MAPK (MEK and ERK) 
phosphorylation, thus suggesting that resistance is not mediated by MAPK 
rescue but rather to compensatory activation of another(s) pathway. Instead, 
PLX4032-resistant BCPAP cells featured sustained pMEK and pERK levels 
even when treated with high doses of drug. Mechanistically, this can be 
explained by compensatory activation of CRAF, since we noted increased 
activatory CRAF phosphorylation in PLX4032-resistant BCPAP cells. 
Whatever the mechanism, it is unlikely that stimulation of MAPK pathway is 
an important component of resistance to PLX4032 because all the three 
PLX4032-resistant cell lines featured also resistance to MEK inhibition. Thus, 
it can be envisaged that activation of non-MAPK based signaling pathways 
may cause such resistance. Accordingly, PLX4032-resistant cells featured 
increased aggressiveness with respect to parental cells characterized by high 
levels of Matrigel invasion and cell motility, a phenotype that is in agreement 
with the possibility that these cells have developed activation of signaling 
pathways in addition to the MAPK one. We found that 2 out of the 3 
PLX4032-resistant cells featured increased phosphorylation of AKT. 
Moreover, preliminary data suggest that also AKT downstream effectors such 
as pS6 have an increased phosphorylation in PLX4032-resistant cells. The 
mechanism of AKT stimulation is still unknown. We excluded RAS mutations 
and PTEN downregulation as well as increased AKT expression (data not 
shown); AKT and PIK3CA sequencing are in progress to verify whether 
mutations at these levels may contribute to pathway activation. Furthermore, 
preliminary data suggest that RTK phosphorylation, in particular IGF1R, may 
be involved. Whatever the mechanism, our data demonstrate that, PLX4032-
resistant cells were sensitive to a PI3K-mTOR double inhibitor, thereby 
suggesting the use of these inhibitors alone or in combination with PLX4032 
as possible strategy to circumvent resistance. 
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Abstract
RET/papillary thyroid carcinoma (RET/PTC) oncoproteins
result from the in-frame fusion of the RET receptor tyrosine
kinase domain with protein dimerization motifs encoded by
heterologous genes. Here, we show that RET/PTC stimulates
the B-catenin pathway. By stimulating PI3K/AKT and Ras/
extracellular signal–regulated kinase (ERK), RET/PTC pro-
motes glycogen synthase kinase 3B (GSK3B) phosphorylation,
thereby reducing GSK3B-mediated NH2-terminal B-catenin
(Ser33/Ser37/Thr41) phosphorylation. In addition, RET/PTC
physically interacts with B-catenin and increases its phospho-
tyrosine content. The increased free pool of S/T(nonphospho)/
Y(phospho)B-catenin is stabilized as a result of the reduced
binding affinity for the Axin/GSK3B complex and activates the
transcription factor T-cell factor/lymphoid enhancer factor.
Moreover, through the ERK pathway, RET/PTC stimulates
cyclic AMP–responsive element binding protein (CREB)
phosphorylation and promotes the formation of a B-catenin-
CREB-CREB-binding protein/p300 transcriptional complex.
Transcriptional complexes containing B-catenin are recruited
to the cyclin D1 promoter and a cyclin D1 gene promoter
reporter is active in RET/PTC–expressing cells. Silencing of
B-catenin by small interfering RNA inhibits proliferation of
RET/PTC–transformed PC Cl3 thyrocytes, whereas a constitu-
tively active form of B-catenin stimulates autonomous
proliferation of thyroid cells. Thus, multiple signaling events
downstream from RET/PTC converge on B-catenin to stimu-
late cell proliferation. [Cancer Res 2009;69(5):1867–76]
Introduction
Papillary thyroid carcinoma (PTC) features chromosomal
aberrations that result in the fusion of the tyrosine kinase domain
of the RET receptor with the NH2 terminus of heterologous
proteins, thereby generating the RET/PTC oncoproteins (1).
Although there is large variation according to the geographic area
and the detection method, the fraction of PTC samples positive for
RET/PTC oncogenes is estimated to be 20% to 40%; this fraction
increases up to 80% in PTC developed in radiation-exposed
individuals (1). RET/PTC1 (H4-RET) and RET/PTC3 (NCOA4-RET)
are the most prevalent variants (1). Fusion with protein partners
that have protein-protein interaction motifs provides RET/PTC
kinases with dimerizing interfaces, thereby resulting in ligand-
independent dimerization and constitutive kinase activation.
Autophosphorylation of RET Y1062 plays a particularly important
role in cell transformation (2). Accordingly, when phosphorylated,
Y1062 acts as the binding site for several protein tyrosine binding
proteins, namely, Shc, IRS1/2, FRS2, and DOK1/4/5 (2). This
mediates recruitment of growth factor receptor binding protein
2/son of sevenless homologue complexes (2–5) and Gab-family
adaptors (2, 6–8) leading to Ras/RAF/extracellular signal–regulated
kinase (ERK) and PI3K/AKT signaling (9–11). Moreover, RET/PTC
depends on the phosphorylation of Y1062 for recruitment at the
inner surface of the cell membrane (2–5).
RET/PTC–mediated transformation requires the Ras/RAF/ERK
cascade (11–13). In line with this observation, oncogenic
conversion of a member of the RAF family, BRAF, is frequently
detected in PTC (1, 14). In addition, deregulation of the PI3K
signaling, through activation of PI3K and AKT serine/threonine
kinase or loss of PTEN phosphatase, is prevalent in thyroid cancer
(15, 16). PI3K signaling is mitogenic for thyrocytes (15, 16).
h-Catenin is a multifunctional protein that plays an important
role in signal transduction. In normal resting cells, h-catenin is
mainly localized to the adherens junctions, whereas free cytosolic
h-catenin is recruited to a ‘‘destruction’’ complex that includes
the scaffolding protein Axin, the tumor suppressor adenomatous
polyposis coli (APC), and glycogen synthase kinase 3h (GSK3h).
This complex facilitates the NH2-terminal serine/threonine phos-
phorylation of h-catenin by GSK3h, thereby targeting h-catenin for
degradation by the ubiquitin-proteasome (17). When the pathway
is activated, as it occurs in the presence of Wnt ligands, h-catenin
is stabilized. Stabilization of h-catenin results in its nuclear
accumulation and interaction with T-cell factor/lymphoid enhanc-
er factor (TCF/LEF) or other transcription factors and in activation
of genes required for cell proliferation (e.g., c-Myc and cyclin D1 ;
ref. 18). PI3K/AKT induces Ser9/21 GSK3h phosphorylation and
inhibition of GSK3h-mediated phosphorylation of h-catenin (19).
p90RSK, a Ras/ERK downstream kinase, also phosphorylates and
inhibits GSK3h thereby leading to h-catenin up-regulation (17, 20,
21). In this pathway, ERK associates with a docking motif, FKFP
(residues 291–294), of GSK3h and phosphorylates it at Thr43 to
prime it for subsequent phosphorylation at Ser9/21 by p90RSK (22).
Up-regulation of h-catenin occurs in a variety of cancers, namely,
colorectal, breast, and ovarian cancers (17, 18). Mutations that
activate h-catenin occur late in thyroid tumor progression, being
detected in undifferentiated (anaplastic) thyroid carcinomas (23).
Increased free h-catenin pools have been observed in thyroid
carcinomas secondary to reduced E-cadherin expression (24). It
has been recently reported that oncogenic point mutants of RET
(2A-RET and 2B-RET), which are associated with medullary thyroid
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cancer, phosphorylate h-catenin on Y654 thereby promoting
h-catenin escape from APC/Axin/GSK3h–mediated destruction
(25). This prompted us to investigate the functional connection
between RET/PTC and the h-catenin signaling cascades.
Materials and Methods
Cell lines. HEK293T cells were grown in DMEM supplemented with
10% FCS (Invitrogen). The human thyroid cancer cell lines, derived from
papillary (TPC-1 and BCPAP) or anaplastic (OCUT-1 and 8505C) thyroid
carcinoma, were grown in DMEM containing 10% fetal bovine serum (FBS).
8505C were from DSMZ (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH). OCUT-1 were a gift of K. Hirakawa and N. Onoda
(Osaka, Japan). TPC-1 harbors a RET/PTC1 rearrangement; BCPAP, OCUT-1,
and 8505C harbor a BRAF V600E mutation (26). Normal human thyrocytes
were isolated from normal thyroid tissue obtained from a patient who
underwent thyroid surgery and cultivated in RPMI supplemented with 20%
FBS. PC Cl3 (hereafter called ‘‘PC’’) is a differentiated thyroid follicular cell
line derived from 18-mo-old Fischer rats. PC cells were cultured in Coon’s
modified Ham’s F-12 medium supplemented with 5% calf serum and a
mixture of six hormones, including thyrotropin (10 milliunits/mL),
hydrocortisone (10 nmol/L), insulin (10 Ag/mL), apo-transferrin (5 Ag/mL),
somatostatin (10 ng/mL), and glycyl-histidyl-lysine (10 ng/mL; Sigma).
RET/PTC–expressing PC cells have been described previously (11). To obtain
PC cells stably expressing the RET/PTC(4F) or RET/PTC(3F) mutants,
transfections were done by the calcium phosphate coprecipitation technique
as described previously (11) and mass populations of several 10 cell clones
were isolated for each transfection by G418 selection. Equal levels of
expression of RET/PTC mutants were confirmed by immunoblotting.
Transient transfections were carried out with the Lipofectamine reagent
according to the manufacturer’s instructions (Life Technologies).
Cell growth and staining. For growth curves, 0.5  105 cells were
seeded in triplicate and counted at the indicated time points. DNA synthesis
rate was measured with the 5¶-bromo-3¶-deoxyuridine (BrdUrd) Labeling
and Detection kit from Boehringer Mannheim. Briefly, cells were seeded
on glass coverslips, pulsed for 1 h with BrdUrd ( final concentration of
10 Amol/L), fixed, and permeabilized. Coverslips were incubated with anti-
BrdUrd mouse monoclonal and rhodamine-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories) and mounted in Moviol
on glass slides. Cell nuclei were identified by Hoechst 33258 ( final
concentration, 1 Ag/mL; Sigma) staining. The fluorescent signal was
visualized with an epifluorescent microscope (Axiovert 2, Zeiss; equipped
with a 100 lens) interfaced with the image analyzer software KS300 (Zeiss).
At least 100 cells were counted in five different microscopic fields; results
were average fractions of BrdUrd-positive cells F SD.
Tissue samples. Archival frozen thyroid tissue samples from 12 patients
affected by PTC (T1–T12) and 2 normal thyroids (N1–N2) were retrieved
from the files of the Pathology Department of the University of Pisa. The
study was approved by the Institutional Ethics Committee. Sections (4 Am
thick) of paraffin-embedded samples were stained with H&E for histologic
examination to ensure that the samples met the diagnostic criteria required
for the identification of PTC (enlarged nuclei with fine dusty chromatin,
nuclear grooves, single or multiple micro/macro nucleoli, and intranuclear
inclusions; ref. 27). According to a previous characterization, three of these
PTC samples had a RET/PTC1 rearrangement (T2, T7, and T12) and six had
a BRAF V600E mutation (T1, T4, T5, T6, T8, and T10; ref. 11). Snap-frozen
tissue samples were kept in liquid nitrogen for storage at 80jC until
protein extraction was done.
Plasmids. Unless otherwise specified, RET/PTC3 is the RET/PTC form
used in this study. The RET/PTC3 constructs were cloned in pBABE and
pCDNA3.1 (Invitrogen). They encode the short (RET-9) RET/PTC3 spliced
form and are described elsewhere (11). For simplicity, we numbered the
residues of RET/PTC proteins according to the corresponding residues in
unrearranged RET. Briefly, RET/PTC(K) is a kinase-dead mutant carrying
the substitution of the catalytic lysine (residue 758 in full-length RET) with a
methionine. RET/PTC(4F) is a mutant in which the four autophosphor-
ylation sites (Y826, Y1015, Y1029, and Y1062) of the COOH-terminal tail
are mutated to phenylalanines; in RET/PTC(3F), the Y1062 has been added
back. Plasmids encoding the dominant-negative Ras(N17), MEK(DN), and
AKT(DN); the constitutively active Ras(V12), BRAF(V600), and h-catenin
(S374A); and the TCF/LEF reporter system are described elsewhere (28).
Antibodies and compounds. Anti-RET is an affinity-purified polyclonal
antibody raised against the tyrosine kinase protein fragment of human RET.
Anti–h-catenin (610153) and anti–E-cadherin (610181) were purchased
from Becton Dickinson (BD Transduction Laboratories). Anti–phospho-
p44/42 mitogen-activated protein kinase [MAPK; recognizing MAPK
(ERK1/2) when phosphorylated either individually or dually on Thr202
and Tyr204], anti–p44/42 MAPK, anti–phospho-AKT (specific for AKT
phosphorylated at Ser473), anti-AKT, anti–phospho-Ser21/9 GSK, anti-GSK,
and anti–phospho-h-catenin (Ser33/37/Thr41) were purchased from Cell
Signaling. Anti-tubulin was from Sigma. Monoclonal anti–phospho-
h-catenin (Y654) antibody was from Abcam. Anti–cyclic AMP-responsive
element binding protein (CREB), anti–phospho-S133 CREB (06-519), and
anti-Tcf4 (05-511) were from Upstate Biotechnology, Inc. Anti–CREB-
binding protein (CBP), anti-p300, anti-SP1, and anti–c-Myc antibody were
from Santa Cruz Biotechnology. Secondary antibodies coupled to
horseradish peroxidase were from Amersham Pharmacia Biotech. Cyclo-
heximide was purchased from Sigma and used at 10 Ag/mL final
concentration. LY294002 was from Calbiochem (Merck Chemicals Ltd.)
and used at 10 Amol/L final concentration. MAPK/ERK kinase (MEK)-1/2
inhibitor UO126 was from Cell Signaling and used at 10 Amol/L final
concentration.
Protein studies. Immunoblotting experiments were done according to
standard procedures. Protein concentration was estimated with a modified
Bradford assay (Bio-Rad). Immune complexes were detected with the
enhanced chemiluminescence kit (Amersham Pharmacia Biotech). Signal
intensity was analyzed with the Phosphorimager (Typhoon 8600, Amersham
Pharmacia Biotech) interfaced with the ImageQuant software. For
immunoprecipitations, total lysates were incubated with 2 Ag antibody
for 2 h at 4jC. Antibody-antigen complexes were collected with 30 AL of
protein G-Sepharose or protein A-Sepharose beads overnight at 4jC with
gentle rotation. The samples were centrifuged, washed, eluted in sample
buffer, and run on SDS-polyacrylamide gel. Nuclear extraction was done
as described elsewhere (29). Briefly, cells were harvested in lysis buffer
[10 mmol/L Tris-HCl (pH 7.9), 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L
DTT, 1 mmol/L phenylmethyl-sulfonylfluoride (PMSF), supplemented with
60 mmol/L NaF, 60 mmol/L h-glycerophosphate, and protease inhibitors
(aprotinin, leupeptin, and pepstatin; 40 mg/mL)] and lysed by shearing with
15 passages through a 26-gauge needle mounted in a 1-mL syringe. Nuclei
were recovered by centrifugation at 3,000  g for 10 min. Nuclear proteins
were extracted in 50 mmol/L Tris-HCl (pH 7.5), containing 0.3 mol/L
sucrose, 0.42 mol/L KCl, 5 mmol/L MgCl2, 0.1 mmol/L EDTA, 20% glycerol,
2 mmol/L DTT, 0.1 mmol/L PMSF, 60 mmol/L NaF, 60 mmol/L h-
glycerophosphate, leupeptin, and aprotinin. Cytosolic fractions were recov-
ered after membrane fraction removal by 100,000  g ultracentrifugation.
Pull-down assay. The GST-RET/PTC3 and GST-RET/TK plasmids were
generated by PCR amplification of full-length RET/PTC3 or the isolated RET
component of the RET/PTC3 protein (RET residues 718–1072) and fusion to
the glutathione S-transferase (GST) coding sequence into the pEBG vector
(kindly provided by S. Meakin, Laboratory of Neural Signaling, Cell Biology
Group, The John P. Robarts Research Institute, London, Ontario, Canada;
ref. 30). GST-RET/PTC3 and GST-RET/TK fusion proteins were purified
from transiently transfected cell lysates using glutathione-Sepharose
according to standard procedures. HEK293T cells were serum starved for
18 h and lysed in an ice-cold buffer. Protein lysates (2 mg) were incubated
overnight with 30 Ag of GST-RET/PTC3 and GST-RET/TK fusion proteins.
Pellet beads were collected by centrifugation (14,000  g ) and washed with
lysis buffer. The beads were resuspended in 2 Laemmli buffer and
subjected to Western blotting.
Reporter assay. To evaluate the TCF/LEF transcriptional activity, we
used a pair of luciferase reporter constructs, TOP-FLASH and the negative
control FOP-FLASH (Upstate Biotechnology). TOP-FLASH contains three
copies of the TCF/LEF binding site (AAGATCAAAGGGGGT) upstream of
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the thymidine kinase minimal promoter; FOP-FLASH contains a mutated
TCF/LEF binding site (AAGGCCAAAGGGGGT). Cells were transiently
transfected by one of these reporters together with pRL-TK (encoding the
Renilla luciferase) in triplicate, as instructed by the manufacturer (Promega
Corporation). Luciferase activity was measured 48 h after transfection with
the Dual-luciferase reporter assay system (Promega). TCF/LEF activity was
determined by the TOP-FLASH/FOP-FLASH ratio after normalization for
Renilla luciferase activity. Light emission was quantified with a Berthold
Technologies luminometer (Centro LB 960). Data were represented as
average fold change F SD with respect to the negative control.
RNA silencing. Predesigned duplex small interfering RNA (siRNA)
against rat h-catenin (190086, 190087, and 190088) were provided by
Ambion. The scrambled oligonucleotide was synthesized by Proligo, and
the sequence was 5¶-AGGAUAGCGUGGAUUUCGGUTT-3¶. The day before
transfection, cells were plated in six-well dishes at 30% to 40% confluency.
Transfection was done using 5 Ag of duplex RNA and 6 AL of Oligofectamine
reagent (Invitrogen). Cells were harvested at 48 h posttransfection or
counted at different time points for evaluating cell growth.
Chromatin immunoprecipitation. Chromatin was extracted from
RET/PTC– or empty vector–transfected HEK293T cells. Chromatin
immunoprecipitation assay was done by using the chromatin immunopre-
cipitation assay kit (Upstate Biotechnology), following the manufacturer’s
instructions. Chromatin was fixed by directly adding formaldehyde (1%, v/v)
to the cell culture medium. Nuclear extracts were isolated and then
Figure 1. RET/PTC stabilizes h-catenin and promotes its nuclear accumulation. A, immunofluorescence for h-catenin in PC cells transiently transfected with
RET/PTC. Note the increase of nuclear staining in transfected cells. Hoechst stain was used to visualize cell nuclei; parallel transfection with green fluorescent protein
showed that f20% of the cells expressed exogenous DNA (data not shown). B, nuclear translocation of h-catenin on RET/PTC expression. HEK293T cells were
transfected with RET/PTC or the indicated mutants [mock transfected (Control )]. PC-RET/PTC cells or parental PC were also used. Subcellular fractions were obtained
and nuclear extracts (50 Ag) probed with anti–h-catenin. The purity of the fractions was assessed by verifying the absence of SP1 in the cytosolic fraction and of
RET/PTC in the nuclear fraction. Total h-catenin levels were also measured in unfractionated extracts. Columns, mean percentage of nuclear h-catenin with respect to
total levels from five independent determinations; bars, SD. Reported P values were calculated by Student’s t test. C, HEK293T cells transiently expressing RET/PTC
or a control vector were treated with cycloheximide for different time points. Lysates (30 Ag) were run on SDS-PAGE, and h-catenin levels were determined by
immunoblot.
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fragmented through sonication. Transcription factor–bound chromatin was
immunoprecipitated with h-catenin, CREB, or TCF antibodies; cross-linking
was reversed; and the isolated genomic DNA amplified by quantitative
PCR using primers spanning either the CRE site (Fig. 4D) or the TCF/LEF
binding site (data not shown) of the human cyclin D1 promoter:
CRE-forward , 5 ¶-AACGTCACACGGACTACAGG-3 ¶; CRE-reverse,
5¶-TGTTCCATGGCTGGGGCTCTT-3¶; TCF-forward, 5¶-GAGCGCATGC-
TAAGCTGAAA-3¶; TCF-reverse, 5¶-GGACAGACGGCCAAAGAATC-3¶.
Figure 2. RET/PTC induces the dissociation of the h-catenin degradation complex. A, HEK293Tcells were transfected with a myc-tagged Axin together with RET/PTC
or the indicated mutants. Protein complexes containing Axin were recovered by immunoprecipitation (1 mg) with anti-myc tag and blotted against h-catenin or
S/T-phosphorylated h-catenin (phospho-Ser33/37/Thr41). Myc-Axin and RET/PTC protein levels in total cell lysates are shown for normalization. B and C,
phosphorylation levels of GSK3h, h-catenin (phospho-Ser33/37/Thr41), AKT, ERK, and RET (Y905) were measured by immunoblot of total cell lysates (50 Ag)
harvested from HEK293T (B) or PC (C ) cells expressing the indicated RET/PTC variants or treated with the indicated compounds. GSK3h antibodies may recognize
both GSK-3a (51 kDa) and GSK3h (46 kDa) proteins; *, GSK3h migration (C ). D, nuclear accumulation of h-catenin (measured as in Fig. 1B ) in HEK293T cells
transfected with RET/PTC and treated or not with chemical PI3K or MEK inhibitors. Representative data of at least three independent experiments.
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Fluorescent threshold values (C t) were measured in triplicate for
immunoprecipitated samples as well as for an aliquot of the input DNA.
Results were calculated by the following formula: 2[DC t/C t input DNA],
where DC t is the difference between the C t of the specific antibody-
immunoprecipitated DNA and the C t of mock-immunoprecipitated DNA.
Results are average F SD of triplicate samples.
Statistical analysis. Student’s t test was used for statistical analysis. All
P values were two sided and differences were significant when P < 0.05.
Results
RET/PTC promotes the nuclear accumulation of B-catenin.
Thyroid follicular PC cells transiently transfected with RET/PTC
accumulated nuclear h-catenin, a hallmark of h-catenin activation
(Fig. 1A). By biochemical fractionation, although total h-catenin
levels were increased on RET/PTC expression, nuclear h-catenin
levels were proportionally increased to a greater extent, thereby
accounting for the increase in the nuclear h-catenin fraction in
HEK293T or PC cells [7-fold (P < 0.001) or 3.6-fold (P < 0.01),
respectively] on transient or stable RET/PTC expression (Fig. 1B).
h-Catenin nuclear accumulation depended on RET/PTC kinase
activity because it was reduced by a kinase-dead mutant (K). The
residual, albeit not significant, activity of PTC(K) might depend
on RET kinase rescue operated by other tyrosine kinases, such
as epidermal growth factor receptor, as recently shown (31).
Moreover, h-catenin accumulation depended on RET/PTC auto-
phosphorylation because it was not exerted by a RET/PTC mutant
(PTC-4F) whose major autophosphorylation sites (Y826, Y1015,
Y1029, and Y1062) were mutated to phenylalanine (Fig. 1B). Y1062
was essential because nuclear accumulation of h-catenin was
restored when tyrosine Y1062 was added back to the 4F mutant
(PTC-3F; P < 0.01; Fig. 1B). There was no detectable difference
in the mRNA levels of h-catenin between RET/PTC–positive and
RET/PTC–negative cells, which suggests that the increase in
h-catenin occurred at the posttranscriptional level (data not
shown). Accordingly, the half-life of h-catenin increased in RET/
PTC–expressing cells (>24 hours) versus control HEK293T
(f12 hours; Fig. 1C).
RET/PTC targets the Axin-GSK3B-B-catenin complex. The
pathway leading to h-catenin activation involves a series of events
that result in the dissociation of h-catenin from Axin, a scaffold
protein that forms a large molecular complex with APC, Dsh, and
GSK3h (17, 18). Transient RET/PTC expression in HEK293T cells
decreased the amount of h-catenin coprecipitating with myc-
tagged Axin; this effect depended on Y1062, as shown when we
used the PTC-4F mutant (Fig. 2A). Secondary to the assembly of
the Axin-GSK3h-h-catenin complex, phosphorylation of h-catenin
by GSK3h in NH2-terminal Ser33, Ser37, and Thr41 promotes its
ubiquitin-dependent proteolytic degradation (19–22). RET/PTC
expression in HEK293T reduced amounts of S/T-phosphorylated
h-catenin coprecipitating with Axin (Fig. 2A). Moreover, transient
RET/PTC expression in HEK293T (Fig. 2A and B) and stable
expression in PC (Fig. 2C ) reduced overall S/T h-catenin
phosphorylation by immunoblot, an effect that depended on
RET/PTC kinase and Y1062 (Fig. 2B). h-Catenin phosphorylation is
affected by GSK3h. In turn, the activity of GSK3h can be blocked
by both AKT- (19) and ERK pathway–mediated phosphorylation
at Ser9 (22). RET/PTC stimulates both the PI3K/AKT and the
ERK pathways by recruiting several adaptors to phosphorylated
Y1062 (2). RET/PTC–triggered phosphorylation of AKT and
ERK paralleled the phosphorylation of GSK3h-Ser9 and the
consequent reduction of phospho-S/T h-catenin (Fig. 2B and C).
PTC-4F had a significantly reduced activity with respect to wild-
type RET/PTC (Fig. 2B). In addition, PTC-3F (although expressed
at lower levels) had a reduced effect on GSK3h phosphorylation,
suggesting that COOH-terminal tyrosines other than Y1062 may
participate to this pathway. LY294002, a PI3K inhibitor, partially
impaired GSK3h phosphorylation and increased h-catenin S/T
phosphorylation; these effects were associated with a reduction in
AKT phosphorylation (Fig. 2B). In addition, treatment with U0126,
a MEK inhibitor, reduced phosphorylation of GSK-3h and partially
rescued phospho-S/T h-catenin (Fig. 2B). Finally, treatment with
LY294002 or U0126 reduced nuclear accumulation of h-catenin
(Fig. 2D).
RET/PTC increases B-catenin phosphotyrosine content. h-
Catenin interacts directly with the oncogenic tyrosine kinases c-src
Figure 3. RET/PTC interaction with
h-catenin. A, protein lysates (2 mg) from
mock-transfected or RET/PTC–transfected
HEK293T cells were immunoprecipitated
with anti–h-catenin and probed with
tyrosine-phosphorylated h-catenin
(pY654), RET, or E-cadherin antibodies.
Expression levels in total cell lysates are
shown for normalization. B, full-length
RET/PTC3 and the isolated RET
component of the RET/PTC3 (deprived of
the NCOA4 region) protein were produced
as GST-fusion proteins and used to pull
down h-catenin from HEK293T protein
lysates. Immunoblot was stained with
anti–h-catenin; recombinant RET proteins
input is also reported.
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(32), c-MET (33), RON (34), c-erbB-2 (35), and BCR-ABL (36),
thereby resulting in h-catenin phosphorylation on tyrosine
residues. More importantly, Gujral and colleagues (25) recently
reported that MEN2-associated RET point mutants bind to
h-catenin and phosphorylate it on tyrosine 654. We tested
whether this mechanism was also used by RET/PTC. In HEK293T
cells, RET/PTC coimmunoprecipitated with h-catenin (Fig. 3A),
and on RET/PTC expression, tyrosine-phosphorylated h-catenin
(pY654) increased; overall increased h-catenin levels may partially
account for these effects (Fig. 3A). The binding of h-catenin to
RET/PTC paralleled its dissociation from E-cadherin (Fig. 3A).
Moreover, recombinant GST-RET/PTC3 and GST-RET/TK proteins
were able to pull down h-catenin from HEK293T cell lysates,
showing an interaction, either direct or mediated by intermediate
protein(s), between the RET component of RET/PTC and h-catenin
(Fig. 3B).
RET/PTC stimulates TCF/LEF– and CREB-mediated cyclin
D1 transcription. Nuclear h-catenin forms complexes with
members of the TCF and LEF family of DNA-binding proteins,
and this process results in activation of target gene promoters.
RET/PTC stimulated the activity of a luciferase TCF/LEF–
dependent reporter gene system (TOPflash) in both HEK293T
and PC cells (P < 0.01; Fig. 4A). The mutant TOPflash reporter
(FOPflash), bearing a mutated TCF/LEF site, was used to subtract
background. This activity depended on the integrity of the RET/
PTC kinase and of the Y1062 multidocking site (P < 0.05; Fig. 4A,
left). Again, other tyrosines besides Y1062 likely played a role
because the PTC-3F mutant was impaired with respect to wild-
type RET/PTC (Fig. 4A, left). TOPflash expression was partially
reduced by treatment with LY294002 and U0126 and by the
coexpression of dominant negative mutants for Ras (N17), MEK
(MEKDN), and AKT (AKTDN; P < 0.05). Constitutively active BRAF
(V600E) and Ras (V12) stimulated the TCF/LEF reporter in
HEK293T cells, although to a lesser extent than RET/PTC. A
transcriptionally active form of h-catenin (S374A) served as a
positive control (Fig. 4A).
Besides TCF/LEF, h-catenin recruits the activated form (serine
133 phosphorylated) of CREB, thereby resulting in a transcrip-
tionally active complex, which in turn binds CBP/p300 (37–40).
TCF/LEF and CREB collaborate in regulating the transcription of
TCRa (41) and WISP-1 (42). Finally, RET signaling through Y1062
and Ras/ERK increases S133 phospho-CREB levels (2). To
determine whether RET/PTC affected the binding of CREB to
h-catenin, we immunoprecipitated h-catenin from PC cells in the
presence or absence of RET/PTC and probed the immunocom-
plexes with anti-CREB and anti-CBP/p300 antibodies. Expression
of RET/PTC significantly increased the amounts of h-catenin
bound to CREB and CBP/p300 (Fig. 4B). Chemical blockade of
MEK by U0126 reduced this association, and this effect was
paralleled by a reduction in CREB phosphorylation on Ser133 and
ERK phosphorylation (Fig. 4B). In a mirror experiment, RET/PTC
expression increased not only TCF/LEF-h-catenin (Fig. 4C,
bottom) but also CREB-h-catenin protein complexes (Fig. 4C,
top). In HEK293T cells, formation of both complexes was reduced
when kinase-dead and 4F mutants were used (Fig. 4C, right).
Instead, by immunoprecipitating CREB and staining with TCF/
LEF, we did not detect TCF/LEF-CREB interaction, suggesting that
h-catenin–containing TCF/LEF and CREB complexes are distinct
(Fig. 4C, middle).
Cyclin D1 promoter contains adjacent TCF/LEF (at 81 bp) and
CREB (at 58 bp) binding sites (40). We used chromatin
immunoprecipitation to measure h-catenin, TCF/LEF, and CREB
binding to the region of the cyclin D1 promoter that contains CREB
and TCF/LEF binding sites. For PCR, we used two primer pairs
spanning the CRE (Fig. 4D) and TCF (data not shown) sites,
respectively. With both primer sets, binding of h-catenin, TCF/LEF,
and CREB to the cyclin D1 promoter was greatly increased on
RET/PTC expression (P < 0.05; Fig. 4D). Because the binding sites
for CREB and TCF/LEF are just a few nucleotides apart on the
cyclin D1 promoter, this experiment left open possibilities that
the two h-catenin–containing (CREB and TCF/LEF) complexes can
be either identical or distinct; however, the lack of coimmunopre-
cipitation in Fig. 4C favors the possibility that the two complexes
are distinct.
RET/PTC–mediated mitogenic signaling depends on B-
catenin. In PC cells, RET/PTC–mediated increase in h-catenin
activity was paralleled by accumulation of the TCF/LEF and CREB
target protein cyclin D1 and, more weakly, c-Myc (Fig. 5A). We
knocked down h-catenin by RNA interference in parental and
RET/PTC–expressing PC cells. As shown in Fig. 5A , h-catenin–
specific siRNA, but not the scrambled control, reduced the
expression of h-catenin by >50% in both PC and PC-PTC cells.
Moreover, h-catenin siRNA reduced cyclin D1 and, more weakly,
c-Myc levels in RET/PTC–expressing cells. h-Catenin RNA
interference reduced hormone-independent proliferation of PC-
PTC cells (Fig. 5B, bottom), whereas a constitutively active form of
h-catenin (S374A) stimulated hormone-independent growth of PC
cells (Fig. 5B, top). We generated mass populations of PTC-4F– and
PTC-3F–expressing PC cells. On hormone deprivation, we counted
S-phase cells on a 1-hour BrdUrd pulse after transient transfection
with scrambled or h-catenin specific siRNA. Similarly to wild-type
PTC, PTC-3F–expressing, but not PTC-4F–expressing, cells incor-
porated BrdUrd in the absence of hormones in a h-catenin–
dependent manner (P < 0.01). Taken together, these findings show
that h-catenin is a mediator of the RET/PTC mitogenic signaling
in thyrocytes.
Finally, to study the h-catenin pathway in human PTC samples,
we measured levels of GSK3h-Ser9 and S/T h-catenin phosphor-
ylation compared with normal thyroid samples (n = 2) in a small
set of PTC (n = 12) samples (three RET/PTC positive, six BRAF
V600E positive, and the remainder RET/PTC and BRAF negative).
Reduced levels of h-catenin S/T phosphorylation was visible in
virtually all the tumor samples; increased levels of GSK3h-Ser9
phosphorylation and total h-catenin were detectable inf75% and
50% of them, respectively (Fig. 5D, left). Similarly, thyroid
carcinoma cell lines positive either for RET/PTC1 (TPC-1) or for
BRAF V600E (BCPAP, 8505C, and OCUT-1) showed reduced levels
of S/T h-catenin and increased GSK3h-Ser9 phosphorylation
when compared with a primary culture of normal thyrocytes
(Fig. 5D, right).
Discussion
Here we describe the functional interaction between the RET/
PTC and the h-catenin signaling pathways. h-Catenin activation
by RET/PTC occurred through several coordinated mechanisms
(Fig. 6). As previously reported by Gujral and colleagues (25) for
point mutant RET, RET/PTC induced the tyrosine phosphorylation
of h-catenin, thereby mobilizing the fraction of h-catenin
associated to E-cadherin and increasing its free cytosolic pool.
RET/PTC-mediated activation of PI3K/AKT and Ras/ERK contrib-
uted to promote h-catenin stabilization through inactivation of
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Figure 4. RET/PTC–mediated activation of TCF/LEF and CREB transcription factors. A, HEK293T (left) and PC-PTC cells (right ) were transfected with the indicated
plasmids together with the TOPflash reporter and, when indicated, treated with the chemical inhibitors. Luciferase activity was expressed as fold increase with respect to
mock-transfected cells. Columns, average results of three independent assays; bars, SD. Reported P values were calculated by Student’s t test. B, cellular lysates
(1 mg) from PC and PC-PTC cells, treated or not with U0126, were immunoprecipitated with anti–h-catenin and probed with CREB and CBP/p300 antibodies. The
CREB antibody may also recognize, besides CREB (43 kDa), CREM (30 kDa) and activating transcription factor-1 (38 kDa); *, CREB migration. Phosphorylation of
CREB (S133) and ERK (MAPK) was measured in total cell lysates by immunoblot. Tubulin was used for normalization. C, lysates from PC or PC-PTC cells (left ) and
HEK293T cells transiently expressing the indicated RET/PTC constructs (right ) were immunoprecipitated with CREB and TCF antibodies and probed for h-catenin
or TCF antibodies, as reported. D, chromatin immunoprecipitation (ChIP) was done in HEK293T cells transfected with RET/PTC or the empty vector (control ).
Processed DNA was immunoprecipitated with TCF, h-catenin, or CREB antibodies and subjected to real-time PCR (bar graphs ) with amplimers spanning the CRE site
of the cyclin D1 promoter. Columns, mean of triplicate samples; bars, SD. Fluorescent threshold values (C t) were measured for immunoprecipitated samples as well
as for an aliquot of the input DNA. Reported P values were calculated by Student’s t test. Semiquantitative PCR (ethidium bromide stain) was also done with the
same primers by using 1 AL of the DNA and 25 cycles of amplification. Amplification of the expected fragments in the input samples indicated equal input; mock PCR
was done without template.
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Figure 5. h-Catenin contributes to autonomous growth of RET/PTC–expressing thyroid cells. A, h-catenin was knocked down by transient transfection with specific
siRNA (si b-catenin ) in parental or RET/PTC–expressing PC cells. As a control, cells were treated with scrambled siRNA (si scrambled ). Protein levels were measured
by immunoblot with the indicated antibodies. B, proliferation in the absence of hormones of parental, constitutively active h-catenin (S374A) or h-catenin siRNA
transiently transfected PC or PC-PTC cells was measured by cell counts. Points, mean of triplicate samples; bars, SD. Reported P values were calculated by Student’s
t test. C, mass populations of PTC-4F– and PTC-3F–expressing PC cells were generated by stable transfection and marker selection. On hormone deprivation
and transfection with scrambled or h-catenin–specific siRNA (as in A), cells were pulsed (1 h) with BrdUrd, and BrdUrd-positive cells were analyzed by
immunofluorescence. At least 100 cells were counted in five different microscopic fields. Columns, mean fractions of BrdUrd-positive cells; bars, SD. Reported P values
were calculated by Student’s t test. D, phosphorylation levels of GSK3h and h-catenin (phospho-Ser33/37/Thr41) were measured by immunoblot of total cell
lysates (50 Ag) harvested from PTC (T1–T12) and normal thyroid (N1–N2 ) tissue samples (left ) or thyroid carcinoma and normal human primary cells (NT ; right ).
GSK3h antibodies may recognize both GSK-3a (51 kDa) and GSK3h (46 kDa) proteins; *, GSK3h migration.
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GSK3h. However, neither pathway was probably sufficient because
chemical blockade of either one reduced but did not abrogate
h-catenin accumulation. Finally, RET/PTC signaling favored the
formation of transcriptional complexes containing h-catenin by
triggering ERK-mediated CREB phosphorylation. Ser133-phosphor-
ylated CREB formed a protein complex with CBP and h-catenin,
which participated in the transcription of cyclin D1. TCF/LEF and
CREB binding sites coexist in the promoters of some h-catenin
target genes, such as cyclin D1 (40), TCRa (41), and WISP-1 (42),
and collaborate in their firing. Accordingly, our findings suggest
that downstream of RET/PTC, h-catenin participates in two
distinct transcriptional complexes, one with TCF/LEF and another
one with CREB, and that both are recruited to cyclin D1 promoter.
The particularly important role played by Y1062 in signaling to
h-catenin in the case of RET/PTC with respect to full-length
RET mutants (25) may be explained by differential signaling
mechanisms between the distinct RET oncogenic forms and the
cytosolic localization of RET/PTC that relies on Y1062 to be
recruited to the cell membrane (2–4). Finally, h-catenin expression
is required for RET/PTC–mediated autonomous proliferation of
PC thyrocytes.
It is possible that h-catenin activity cooperates with other
signaling cascades activated by RET/PTC to mediate mitogenic
activity. Cytosolic h-catenin is recruited to a ‘‘destruction’’ complex
that includes APC and GSK3h. Loss of APC tumor suppressor
reduces the activity of the h-catenin destruction complex (17, 21).
Of direct relevance to thyroid tumorigenesis, patients affected
by familial APC [familial adenomatous polyposis (FAP)] and
harboring APC mutations are predisposed to thyroid carcinoma
(43). Furthermore, the RET/PTC oncogene is activated in some
FAP-associated thyroid carcinomas (44). Therefore, our data
support a model whereby two different lesions concomitantly
present in FAP-associated thyroid carcinoma (i.e., RET/PTC
activation and APC loss of function) may converge to enhance
the activity of the h-catenin signaling cascade. On the other hand,
direct h-catenin mutations are restricted to aggressive and
undifferentiated types of thyroid carcinomas (23).
h-Catenin targeting approaches for cancer therapy are currently
being explored. For example, a conditionally replicative adenovirus,
which kills only cells with a hyperactive h-catenin pathway,
significantly inhibited the growth of undifferentiated (anaplastic)
thyroid cancers (45). ICG-001, an inhibitor of the h-catenin/CBP
transcriptional complex, efficiently induced apoptosis of colon
cancer cells (46). Prostaglandin E2 (PGE2) also promotes h-catenin
signaling (28), and PGE2 synthesis inhibitors, nonsteroidal anti-
inflammatory drugs, in an adjuvant or preventive setting are being
tested already in cancer. Our data, together with those reported by
Gujral and colleagues (25), suggest that h-catenin targeting
approaches could have therapeutic potential in thyroid cancer.
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Figure 6. A summary of the pathways
leading to h-catenin induction by RET/PTC.
1 and 2, RET/PTC activates PI3K/AKTand
Ras/MEK/ERK. This leads to GSK3h
phosphorylation, thereby relieving its
negative control on h-catenin, and to an
increase of the free h-catenin protein pool.
2, through ERK activation, RET/PTC
induces S133 phosphorylation of CREB,
which associates in a complex with
h-catenin and CBP/p300 to stimulate
transcription of cyclin-D1. 3, RET/PTC
directly binds h-catenin and increases its
phosphotyrosine content, thereby
decreasing the E-cadherin–bound pool and
increasing the free h-catenin pool. Free
h-catenin enters the nucleus and
participates in at least two different
transcription complexes with CREB/p300
and with TCF/LEF, both ultimately involved
in the regulation of cyclin D1.
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Summary
Context In multiple endocrine neoplasia (MEN), rearranged
during transfection (RET), gene testing has been extensively
exploited to characterize tumour aggressiveness and optimize the
diagnostic and clinical management.
Objective To report the underlying genetic alterations in an
unusual case of MEN type 2 (MEN-2A).
Design and patient Occult medullary thyroid carcinoma
(MTC) was diagnosed in a 44-year-old man who had presented
with unilateral phaeochromcytoma. DNA extracted from the blood
and tumour tissues was analysed for mutations in RET. The trans-
forming potential and mitogenic properties of the identified RET
mutation were investigated.
Results The patient carried a novel heterozygous germ-line RET
mutation in exon 5 (Val292Met, GTG>ATG) (V292M/RET) with
no evidence of additional somatic alterations. The mutation maps
to the third cadherin-like domain of RET, which is usually not
included in RET screening. Interestingly, MTC with concomitant
phaeochromcytoma has never been associated with a RET muta-
tion involving the extracellular cadherin-like domain. V292M/RET
was absent in the only two relatives examined. In vitro assays indi-
cate that the mutant has low-grade transforming potential.
Conclusions Complete characterization and classification of all
novel RET mutations are essential for extending genetic analysis in
clinical practice. Our findings suggest that: (i) in all MEN-2
patients negative for RET hot-spot mutations, testing should be
extended to all coding regions of the gene and (ii) the newly identi-
fied V292M/RET mutation is characterized by relatively weak
in vitro transforming ability.
(Received 29 July 2009; returned for revision 10 August 2009;
finally revised 28 October 2009; accepted 30 November 2009)
Introduction
Genetic testing is a cornerstone of medullary thyroid carcinoma
(MTC) management,1–3 and screening for germ-line mutations in
the rearranged during transfection (RET) proto-oncogene4 is now
done routinely in multiple endocrine neoplasia type 2 (MEN-2)
patients and their relatives.5 This approach has revolutionized the
management of MTC by allowing preclinical identification of fam-
ily members at risk. Knowledge of the specific mutation can also
guide clinical decisions, including those regarding the timing of
prophylactic thyroidectomy, which significantly improves the
prognosis, and intraoperative management of the cervical lymph
nodes and parathyroid glands.6–8 Equally important, RET testing
also spares noncarriers the ordeal and anxiety of yearly surveillance
for cancer. Optimal interpretation of test results naturally requires
thorough knowledge of each mutation, its relative tumourigenic
potency, and its precise phenotypic correlates.
Most laboratories focus on the hot-spot RET exons (10, 11, 13,
14, 15 and 16), where the vast majority of the reported mutations
are found.6,9–11 This approach is generally cost-effective although
MEN-2A (the most common form of the MEN-2 syndrome) is
occasionally associated with mutations in other RET regions.5 A
few families have also been found to be negative for all known RET
mutations, suggesting that predisposition to MEN-2 may also be
caused by mutations at other loci.12
We report a patient with a MEN-2A phenotype consisting of
unilateral phaeochromcytoma (the presenting manifestation of the
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disease) and MTC. Genetic studies ultimately revealed a germ-line
RET mutation in exon 5, which has not been previously described.
In vitro experiments were performed to characterize its biological
activity and relevance to the MEN-2A phenotype.
Materials andmethods
All subjects provided written, informed consent to genetic studies
and to publication of the findings reported later. Commercial
products were used according to manufacturers’ instructions
unless otherwise stated.
Patient description
A 44-year-old man presented with a 2-year history of paroxysmal
headaches associated with sweating, palpitations, tremor, dizziness,
hypertension (240/110 mmHg). Physical examination was unre-
markable, but biochemical evaluation revealed elevated urinary
catecholamines (Table 1). Computed tomography disclosed a large
right adrenal mass, which later displayed high uptake of metaiod-
obenzylguanidine. Serum calcium and phosphate levels were nor-
mal. The basal serum calcitonin level was normal. Neck
ultrasonography disclosed a hypoechoic nodule (6 mm) with mic-
rocalcifications in the upper third of the right thyroid lobe, which
presented at ultrasound-guided fine needle aspiration cytological
findings suggestive of thyroid cancer.
The right adrenal tumour was surgically resected and histologi-
cally diagnosed as phaeochromcytoma. After surgery, urinary cate-
cholamine levels normalized, and the hypertensive episodes ceased.
Six weeks later, total thyroidectomy was performed with dissection
of four lymph nodes. Histology revealed the presence of a 4-mm
unifocal MTC, with typical immunostaining features (calcitonin
positivity, thyroglobulin negativity). In addition, foci of C cell
hyperplasia were also present in both thyroid lobes. All four
resected lymph nodes were negative for metastatic infiltration.
DNA sequence analysis
RET exons 5, 8, 10, 11, 13, 14, 15, 16 and 18 were analysed by direct
sequencing in DNA extracted from peripheral blood (QIAamp-
Blood MIDI kit; Qiagen, Valencia, CA, USA) and formalin-fixed,
paraffin-embedded tumour tissues (Nucleon HT kit; Amersham
Pharmacia Biotech, Milan, Italy) (For primers see Table 2). In DNA
from the phaeochromcytoma, we also sequenced all exons of the
von Hippel-Lindau (VHL) gene and the genes encoding succinate
dehydrogenase subunits B (SDHB) and D (SDHD). The coding
regions and exon–intron boundaries of each gene were amplified
by PCR and the products sequenced with a BigDye Terminator
version 3.1 Cycle Sequencing kit in an automated 3130xl analyzer
(both from Applied Biosystems, Foster City, CA, USA).
Protein studies
Polyclonal rabbit antibodies against RET’s tyrosine kinase domain
(amino acids 738–1058) (anti-RET) or RET proteins phosphory-
lated on tyrosines 1062 and 905 (anti-pY1062 and anti-pY905,
respectively) were affinity-purified by sequential chromatography
on RET- and glutathione-S-transferase-coupled agarose col-
umns.13 We also used antiphospho-Src homologous and collagen
(Shc) (#Y317), which recognizes Shc proteins phosphorylated at
Y317 (Upstate Biotechnology, Inc., Lake Placid, NY, USA); anti-
phospho-MAPK (#9102), which is specific for p44/42MAPK
[extracellular regulated kinases 1 and 2 (ERK1/2)] phosphorylated
at Thr202/Tyr204; and antiphospho-MAPK/ERK kinase 1 and 2
(MEK1/2) (#9121), which is specific for MEK1/2 phosphorylated
at Ser217/Ser221 (both from Cell Signalling, Beverly, MA, USA).
Monoclonal antiphosphotyrosine (4G10) was purchased from
Upstate Biotechnology, Inc. Secondary horseradish peroxidase-
coupled antibodies were from Amersham Pharmacia Biotech
(Little Chalfort, UK, USA). Immunoprecipitation and immuno-
blotting were performed according to standard procedures.14
Molecular constructs
Constructs used in this study encode the RET-9 isoform and were
cloned in pBabe vectors. The wild-type RET (wtRET), C634R/RET
and V804M/RET constructs are described elsewhere.15 V292M/
RET (GTG>ATG) was generated by site-directed mutagenesis
(QuickChange kit; Stratagene, La Jolla, CA, USA) and verified by
DNA sequencing.
Cell transfection experiments
NIH3T3 fibroblasts were grown in DMEM containing 5% calf
serum (GIBCO, Paisley, PA, USA). Stable NIH3T3 transfections
were performed by calcium phosphate precipitation, as described
elsewhere.15 The efficiency of marker-selected colony formation
was roughly 50 colonies per pmol DNA. Transient transfections
(luciferase assays) were carried out with the lipofectamine reagent
according to the manufacturer’s instructions (GIBCO). Parallel
transfection with Green Fluorescent Protein (GFP) showed that
about 20% of the cells expressed exogenous DNA.
Reporter assays
Firefly luciferase reporters were kindly provided by S. J. Gutkind
(NIH, Bethesda, MD, USA). The pGL3-AP-1 (activator protein 1)
and pGL3-SRF (serum response factor) reporters contain five repe-
titions of the target sequence (AP-1 and SRF, respectively)
upstream to the firefly luciferase cDNA. Twenty-four hours after
seeding, cells were transiently transfected in triplicate with one of
Table 1. Laboratory findings for the patient on admission
Parameter Patient Normal values
Urinary adrenalin (lg/24 h) 172 1Æ4–15Æ5
Urinary noradrenalin (lg/24 h) 623 12–85
Serum calcium (mmol/l) 2Æ37 2Æ17–2Æ67
Serum phosphate (mmol/l) 1Æ26 0Æ87–1Æ45
Calcitonin (pg/ml) 16Æ7 <20
Bold values indicate parameter out of the normal range.
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the reporters plus the internal-control pRL-null plasmid expressing
Renilla luciferase (Promega Corporation, Madison, WI, USA).
Forty-eight hours post-transfection cells were serum-starved over-
night. Luciferase activities were assayed with the Dual-Luciferase
Reporter System (Promega Corporation). In all cases, the total
amount of transfected plasmid DNA was normalized with empty
vector DNA.
Results
The family history was negative for thyroid, parathyroid and adre-
nal disease, and direct sequencing of RET exons 10, 11, 13, 14, 15
and 16, and later, exons 8 and 18, revealed no germ-line or somatic
mutations in the patient, although heterozygous single nucleotide
polymorphisms were identified in exons 11 (Gly691Ser,
GGT>AGT), 15 (Ser904Ser, TCC>TCG) and 18 (Arg982Cys,
CGC>TGC) in both peripheral blood and tumour DNA. The pha-
eochromcytoma was also negative for SDHB, SDHD and VHL
mutations (data not shown).
Subsequent extension of RET analysis to exon 5 revealed a novel
heterozygous germ-line mutation at codon 292 (Val292Met,
GTG>ATG) (Fig. 1). The alteration was absent in 100 healthy con-
trols (data not shown) and in the patient’s mother and sister (the
only relatives available for genetic testing).
The in vitro functional characteristics of the V292M/RET muta-
tion are summarized in Fig. 2. Its transforming capacity was
assessed in mass populations of marker-selected NIH3T3 cells
transfected with V292M/RET, wt-RET or C634R/RET, a strongly
oncogenic mutant. As shown in Fig. 2b, V292M/RET transfectants
correctly synthesized Mr 145 000 and Mr 160 000 RET isoforms,
the former representing an immature precursor, the latter a mature
glycosylated protein present on the cell surface.16 We also mea-
sured the in vivo tyrosine phosphorylation levels of the different
RET proteins as read-outs of their oncogenic activation status.
Unlike the wild-type protein, V292M/RET displayed detectable
phosphotyrosine reactivity, but it was approximately 10 times
weaker than that observed in C634R/RET (Fig. 2b). The new muta-
tion’s ability to activate intracellular signalling was reflected by
higher than wild-type levels of phosphorylated MEK, MAPK and
Shc adaptor [which is recruited by phosphorylated RET Y1062 and
stimulates MEK and MAPK (ERK) kinase activity16 (Fig. 2c)].
Analysis of the proliferation rates of transfected and untransfected
NIH3T3 cells under conditions of serum deprivation (1% calf
serum) revealed mitogenic effects for both RET mutants, but those
of C634R/RET were clearly stronger (Fig. 2d). In luciferase reporter
assays (Fig. 2e), we examined also the activity of class A V804M/
RET mutant: all the three mutants stimulated transcription factors
known to be activated by RET. However, the activity of V292M
resulted higher than wild-type RET but lower not only than the
potent C634R but also than the less potent V804M mutant
(Fig. 2e). Evidence of disulphide-bridge-mediated RET dimeriza-
tion was observed only in C634R/RET mutants (data not shown).
Collectively, these findings indicate that the V292M mutation is
a gain-of-function alteration with weaker oncogenic potential than
Fig. 1 Sequence electropherogram for mutation found in exon 5 of RET. The mutation (Val292Met, GTG>ATG) is marked by an arrow, and the wild-type
sequence is shown below for comparison.
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C634R/RET or V804M/RET. Indeed, the number of transformed
foci induced by C634R/RET in NIH3T3 cells was considerably
higher than that observed in V292M/RET transfectants (data not
shown).
Discussion
Genetic analysis now plays integral parts in the management of
MTC and phaeochromcytoma.5,17 The association of these two
tumours is quite common in MEN-2A, but the fact that our
patient’s presenting symptoms were related to the adrenal rather
than the thyroid tumour is atypical, and the family history was neg-
ative for both types of disease. Furthermore, our initial sequencing
studies disclosed no germ-line or somatic mutations involving RET
regions commonly (exons 10, 11, 13, 15 and 16) or less commonly
(exons 8 and 18) altered in MEN-2 syndromes. For these reasons,
we also excluded the presence of mutations in genes – other than
RET – associated with familial or sporadic phaeochromcytoma (i.e.
SDHB, SDHD and VHL).17
We finally discovered a heterozygous germ-line mutation in RET
exon 5, which has never been described before. Pedigree analysis
and the results of genetic testing in the patient’s family (limited to
(a) (b) (c)
(d) (e)
Fig. 2 Results of in vitro tests performed to characterize the V292M/RET mutation. (a) Schematic representation of the RET protein showing cadherin-like
(CLD), cysteine-rich (CRD), transmembrane (TM), juxtamembrane (JM) and tyrosine kinase (TKD) domains and the locations of the V292M mutation and
two other mutations commonly associated with medullary thyroid cancer. (b) Expression levels and phosphorylation status of wild-type (wt) and V292M and
C634R mutant RET proteins in mass populations of stably transfected NIH-3T3 cells. Protein (500 lg) extracts from each cell line were immunoprecipitated
with anti-RET and blotted with anti-RET, phosphorylation-specific (pY1062 and pY905) RET or phospho-tyrosine (pY) antibodies. (c) Protein (100 lg)
extracts from the three transfected cell lines were blotted with phosphorylation-specific MAPK, MEK and Shc antibodies. Tubulin is shown for normalization.
(d) Growth curves of NIH3T3 transfected with empty vector (control), wild-type (wt) RET and V292M and C634R RET mutants. Cells (n = 50 000) were pla-
ted and counted at different time points. (e) Cells were transfected with the indicated plasmids plus V804M RET mutant together with the luciferase reporters
driven by RET-activated transcription factors, SRF and AP1. Luciferase activity is expressed as fold increase of the activity seen in mock-transfected (control)
cells. All data reported above are means (d, e) or representative (b, c) of the results obtained in three independent assays. Standard deviations never exceeded
20%.
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two of the four subjects at risk) indicate that the V292M/RET
mutation is probably a de novo germ-line alteration carried only by
the proband.
The location of the new mutation was surprising. The RET
mutations associated with MEN-2 thus far almost invariably target
the extracellular cysteine-rich box adjacent to the plasma mem-
brane (encoded by exons 10 and 11) or the intracellular tyrosine
kinase domain (Fig. 2a). Our patient’s exon 5 mutation involves
one of the receptor’s four extracellular cadherin-like repeats. There
is only one other report linking MEN-2 to a RET mutation involv-
ing this region:18 it involved a missense glycine for arginine substi-
tution at codon 321 (also in exon 5) found in four members of a
three-generation Czech kindred with FMTC (one with MTC, one
with C-cell hyperplasia and two with no evidence of either). The
authors’ assumption that this mutation causes FMTC was based
exclusively on these findings and the documented absence of muta-
tions in the hot-spot RET exons.18
Legitimate questions can be raised regarding the significance of
this mutation and the one found in our patient. Indeed, on a theo-
retical basis, the hypothesis of a very rare polymorphism cannot be
definitely ruled out, even though the V292M/RET mutation did
not occur in any of the 100 healthy controls. To address this issue,
we investigated the biological activity of V292M/RET mutant con-
structs in vitro. The results are clearly indicative of a gain-of-func-
tion mutation although the molecular mechanism underlying its
activating effects remains unknown. The classic extracellular cyste-
ine-targeting RET mutants promote aberrant inter-chain disul-
phide bonding, which mimics ligand-induced RET
homodimerization.15 By contrast, the constitutive RET activation
produced by the V292M mutant is dimerization-independent,
which is not surprising as it does not affect any of the cysteine resi-
dues. Unfortunately, the structure of the RET extracellular domain
has not been solved yet, and therefore it is difficult to figure out
what type of folding effect may the V292M mutation have. How-
ever, it is worth noting that many other examples of gain-of-func-
tion mutations targeting noncysteine residues of the extracellular
domain of receptor tyrosine kinases other than RET have been
reported in tumours.19,20 The extracellular cadherin-like domains
are thought to play roles in RET’s interaction with its ligands,21 but
our findings demonstrate that alterations in this region can also
lead to ligand-independent RET activation.
RET point mutants associated with MEN-2A (or MEN2-B) gen-
erally display strong transforming potential; those found in FMTC
patients are consistently less potent.4,16 Our in vitro analysis indi-
cates that V292M/RET is a substantially weaker transforming
mutant than C634R/RET or V804M/RET. This finding suggests
that other genetic determinants may also have contributed to the
tumour formation in our patient. Little is known about the impact
of genetic modifiers on MEN-2 phenotypes, but the syndrome’s
variable clinical presentation has been putatively linked to factors
capable of modifying the transformation process.22 More recently,
wide variability in the activated RET-driven MTC phenotype has
been reported in transgenic mice with different genetic back-
grounds: penetrance rates in the different strains ranged from 0%
to 98%, and there were also significant differences in tumour size.23
Susceptibility to MTC seems to be influenced by certain RET
polymorphisms.24–28 Their role in the development of the patient’s
tumours is, however, difficult to prove. Polymorphisms involving
genes whose products interact with RET or components of the RET
signalling pathway have also been reported to modify the risk of
MTC.12,27 Phenotype-modifying effects might also stem from sec-
ondary genetic alterations at the somatic level, which act in concert
with the germ-line RET mutations to trigger MTC development.1,29
The second hit can involve loss of the wild-type RET allele or dupli-
cation of the mutated one30 – events that can be excluded in the
present case – or deletion and amplification of entire chromo-
somes.31
In conclusion, this case illustrates the importance of the Ameri-
can Thyroid Association’s recent recommendation to extend RET
sequencing studies to the gene’s entire coding region when initial
testing of a patient with clinical signs of MEN-2 fails to reveal RET
hot-spot mutations or when genotype-phenotype discrepancies
emerge.5 Re-testing may be warranted in certain cases with MEN-2
phenotypes currently classified as RET-mutation-negative. Failure
to identify the causative mutation has an enormous impact on the
management of these patients and their families, in terms of prog-
nosis, quality of life and health-care costs. Functional characteriza-
tion of newly identified RET mutants is important for estimating
their contribution to cancer-susceptibility phenotypes. The mecha-
nism by which V292M activates RET remains to be defined, and
the current data suggest that it may require the contributions of
other genetic or epigenetic determinants to produce predisposition
to cancer.
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